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 Caspase-9 has two splice variants, pro-apoptotic caspase-9a and anti-apoptotic caspase-9b, 
and dysregulation of caspase-9 splice variant ratio or expression of caspase-9b isoform has been 
linked to augmentation of the anchorage-independent growth and tumorigenic capacity of non-
small cell lung cancer (NSCLC) cells. This study focuses on cell signaling pathway(s) regulating 
the alternative splicing of caspase-9 pre-mRNA and mechanistic roles of caspase-9b in a certain 
oncogenic/survival pathway. In regards to the former, we have identified hnRNP U as a novel 
splice-enhancer associated with exon 3 of caspase-9 (C9/E3). Moreover, hnRNP U binds 
  
specifically to C9/E3 at an RNA cis-element previously reported as the binding site for the 
splicing repressor, hnRNP L. Phosphorylated hnRNP L interferes with hnRNP U for binding to 
C9/E3, and our results demonstrate the importance of the phosphoinositide 3-kinase/AKT 
pathway in modulating the association of hnRNP U to C9/E3. Overall, a mechanistic model has 
been revealed where hnRNP U competes with hnRNP L for C9/E3 binding to enhance the 
inclusion of the four-exon cassette, and this splice-enhancing effect is blocked by the AKT 
pathway via phosphorylation of hnRNP L. As to the latter aim, it is unknown about the 
mechanistic roles of caspase-9b besides the inhibitory effect on caspase-9a processing. In this 
study, caspase-9b has been demonstrated to have a dual function in regulating the 
survival/oncogenic nuclear factor κB (NF-κB) pathway, which is independent from modulating 
caspase-9a activation. In particular, caspase-9b has been shown to activate the canonical arm and 
inhibit the non-canonical arm of the NF-κB pathway by destabilizing NF-κB inhibitor alpha 
(IκB-α) and NF-κB-inducing kinase (NIK). Importantly, this new role for caspase-9b contributes 
to the enhanced survival and anchorage-independent growth of NSCLC cells conferred by 
caspase-9b expression. Further mechanistic studies have demonstrated a direct association of 
caspase-9b with the cellular inhibitor of apoptosis 1 (cIAP1), a regulatory factor in both arms of 
the NF-κB network, via its IAP-binding motif. Through this interaction, caspase-9b induces the 
E3 ligase activity of cIAP1, which regulates NF-κB activation, and promotes the survival, 
anchorage-independent growth and tumorigenicity of NSCLC cells. Overall, a novel tumorigenic 
mechanism has been identified, by which alternative mRNA processing regulates the NF-κB 
signaling independent of external agonist. 
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CHAPTER 1 – INTRODUCTION:  
REGULATION OF CASPASE-9 SPLICING BY HNRNP U 
 
 
 
 
1.1 Non-small cell lung cancer 
Lung cancer is the leading cause of cancer-related death in both men and women worldwide 
and accounts for an estimated 28% of all cancer deaths in the United States (50). Death rates 
from lung cancer have not been changed considerably over the past 50 years despite the 
advances in cancer treatment and improvements in lifestyle and health care. Non-small cell lung 
cancer (NSCLC) represents the majority of lung cancers with poor prognosis and a cumulative 
five-year survival rate of less than 18% (70). Most patients present with unresectable disease and 
therefore, chemotherapy and/or radiation are the current treatment options. However, the 
treatment efficacy is restricted by the rapid development of chemo- or radio-resistance (13). 
Thus, development of new therapy approaches, especially new therapeutic targets, is necessary 
to reduce the mortality from this disease.   
1.2 Apoptosis: the intrinsic and extrinsic pathway 
Apoptosis is a distinctive mode of “programmed cell death”, which plays critical roles in 
regulation of tissue homeostasis (18). Apoptosis process is often energy-dependent, irreversible 
and highly coordinated by a cascade of molecular events. The most important factor mediating 
apoptosis is a group of cysteine proteases called caspases, which are capable of cleaving
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specific proteins in the cytoplasm and nucleus to trigger cell death. Caspases exist in the cells as 
inactive precursors, or procaspases, which are usually activated by other caspases, resulting in a 
proteolytic caspase cascade. Caspase activation is regulated by members of the Bcl-2 family and 
the inhibitor of apoptosis (IAP) proteins.  
Two main apoptotic pathways have been identified: the extrinsic or death receptor pathway 
and the intrinsic or mitochondrial pathway (figure 1.1). Although these two pathways differ in 
the initiation phase, they both end at the point of the execution phase including caspase-3 
activation, DNA fragmentation, degradation of cytoskeletal and nuclear proteins, protein 
crosslinking, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors 
and uptake of apoptotic bodies by phagocytic cells. For the initiation phase in the extrinsic 
pathway, engagement of death receptors results in the formation of the death-inducing signaling 
complex (DISC) containing the death receptors, adaptor proteins, caspase-8 and caspase-10 
whereas the intrinsic pathway is initiated by the release of cytochrome c from the mitochondria 
into the cytosol to trigger the formation of apoptosome containing cytochrome c, apaf-1 and 
caspase-9. Further recruitment of caspases to DISC and apoptosome leads to their activation by 
dimer formation.  
Various key factors in apoptosis have been identified; however, the molecular mechanisms of 
many of these remain inclusive. Since dysregulation of apoptosis, either increased or inadequate 
apoptosis, is implicated in many disease states, including neurodegenerative disorder, acquired 
immune deficiency syndrome (AIDS), ischemic damage, autoimmune disorders and many types 
of cancer, further studies regarding the mechanisms of apoptosis would have significant impacts 
on developing therapeutic strategy against apoptosis-related diseases. 
  
 3 
 
1.3 Caspase-9 splicing 
 Among the 14 caspases identified to date, caspase-9 is one of the most important initiators of 
the intrinsic apoptotic pathway. For example, the activation of caspase-9 via interaction with 
Apaf-1 and cytochrome c to form the apoptosome activates downstream caspases to amplify 
apoptotic signaling. There are two splice variants of caspase-9, caspase-9a and caspase-9b, that 
can be generated by the inclusion or exclusion of exon 3,4,5,6 cassette in the mature caspase-9 
mRNA (figure 1.2). Different from caspase-9a (or procaspase-9), caspase-9b lacks the catalytic 
domain, but retains the caspase recruitment/Apaf-1 association domain (CARD) (figure 1.2). 
Thus, apposing to caspase-9a, which is a pro-apoptotic protein, caspase-9b functions as an 
apoptotic inhibitor by competing with caspase-9a for binding to Apaf-1 and consequently 
suppressing caspase-cascade activation (55, 59). 
 The ratio of caspase-9a/9b isoform is dysregulated in NSCLC cells (21, 57), and several 
factors implicated in regulating the alternative splicing of caspase-9 include endogenous 
ceramides (8), SRSF1 (SRp30a or ASF/SF2) (45, 57, 58) and heterogeneous nuclear 
ribonucleoprotein L (hnRNP L) (21). De novo ceramide synthesis and SRSF1 have been 
documented to down-regulate the level of caspase-9b mRNA in contrast to hnRNP L, which 
represses the inclusion of four-exon cassette to favor the formation of caspase-9b. Importantly, 
phosphorylation of SRSF1 or hnRNP L and subsequent effects on the caspase-9 splicing process 
has been shown to be important in sensitizing non-small cell lung cancer (NSCLC) cells to 
chemotherapeutics and promoting the tumorigenic capacity of these cells (21, 58).  Hence, 
modulation of caspase-9 splicing or caspase-9 splice variant ratio would be a promising cancer-
specific approach for treatment of NSCLC. 
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1.4 hnRNP U protein 
hnRNP U, also known as SP120, is the largest of major heterogeneous nuclear 
ribonucleoproteins (120 KDa). It is capable of binding to both DNA through the acidic region in 
the N-terminal and RNA via the RGG box in the C-terminal (19, 34) (figure 1.3). hnRNP U is 
also a major constituent of nuclear matrix or scaffold and is, thereby, termed scaffold attachment 
factor A (SAF-A). Various biological functions of hnRNP U have been reported: regulation of 
gene transcription (17, 35, 36, 53), controlling RNA stability (68), participating in X inactivation 
process (23, 25) and controlling telomere length (20). The splicing regulatory function of hnRNP 
U has just emerged recently (69) with hnRNP U shown to modulate SMN2 splicing via 
controlling U2 snRNP maturation. The multiple biological roles of hnRNP U might explain why 
mice carrying a hypomorphic mutation in the hnRNP-U gene exhibit post-implantation lethality.  
1.5 Specific aims of the study 
  Previously in the laboratory, four RNA trans-factors were identified to associate with the 
purine-rich sequences in C9/E3, including hnRNP L, hnRNP A2/B1, hnRNP R and hnRNP U 
(Table 1.1), and this association suggested a possible biological function in regulating caspase-9 
mRNA processing (21). The roles of hnRNP L and hnRNP A2/B1 on caspase-9 splicing were 
further examined by Goehe et al in the laboratory (21). In this study, we examined the roles of 
the two other factors, hnRNP U and hnRNP R, on caspase-9 RNA splicing and found the  
involvement of hnRNP U in regulating caspase-9 splicing through interaction with target mRNA. 
The precise binding sites for hnRNP U on caspase-9 mRNA were also determined. Additionally, 
we investigated the mechanism that regulates the interaction between hnRNP U and exon 3 of 
caspase-9, which determines the preferential expression of caspase-9a or caspase-9b.  
 
 5 
 
 
Figure 1.1 Intrinsic and extrinsic pathway in apoptosis. The intrinsic pathway is initiated 
within the cells and is triggered by different signals as a result of DNA damage, severe cell stress 
or loss of cell-survival factors. Activation of the intrinsic pathway normally leads to the release 
of pro-apoptotic proteins from the mitochondria, the center of the intrinsic signaling, to activate 
caspase cascade, including the initiator and effector caspases, and execute apoptosis.  The 
extrinsic pathway is initiated outside the cell via association between the pro-apoptotic ligands 
and pro-apoptotic receptors on the cell surface. Ligand binding results in receptor clustering and 
formation of death-inducing signaling complex (DISC). After DISC activation, the extrinsic 
pathway utilizes the same effector caspase machinery as the intrinsic pathway.     
 
 6 
 
 
Figure 1.2 Schematic representation of caspase-9a/b mRNA and protein structure. The 
alternative splicing of caspase-9, specifically the inclusion or exclusion of the four-exon cassette, 
generates two different splicing products, caspase-9a and caspase-9a. Caspase-9b protein 
translated from caspase-9b splice variant lacks almost the large subunit, including the catalytic 
site.     
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Figure 1.3 Schematic representation of hnRNP U protein structure. hnRNP U contains the 
amino-terminal acidic region, which mediates its binding to DNA sequence termed scaffold 
attachment region (SAR), and RGG box in the carboxy-terminal glycine-rich region, which 
enables it to bind to RNA sequence. NLS and NTP denotes the putative nuclear localization 
signal and NTP binding site.  
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CHAPTER 2 – MATERIALS AND METHODS:  
REGULATION OF CASPASE-9 SPLICING BY HNRNP U 
 
 
 
 
2.1 Cell culture  
 A549 lung adenocarcinoma cells were cultured in DMEM medium with 10% (v/v) FBS 
(Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin sulfate (Invitrogen). Human 
bronchial epithelial primary cells (HBEpC) were cultured in Bronchial/Tracheal Epithelial Cell 
Growth medium (Cell Applications). All cells were maintained at less than 80% confluency 
under standard incubator conditions. For the comparison studies between A549 versus HBEpC 
cell lines, cells were plated in tissue culture plates (100 mm), which gave 40% confluency. The 
following day, medium was changed to serum-free DMEM and cell plates were incubated 
overnight before total protein or cell lysates were isolated for analysis.   
2.2 Electrophoretic mobility shift assay (EMSA)  
 RNA-binding reaction mixtures (20 µl) containing 10 µg of A549 or HBEpC cell lysates, 40 
U RNASIN, 11.3 µg tRNAs, 10 mM  HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, 5% 
glycerol and 10 μM of FITC  tagged RNA oligos (C9/E3 WT, C9/E3 Mut1, C9/E3 Mut2, C9/E3 
Mut3 or C9/E3 Mut4) were incubated on ice for 20 minutes. Then 2 µg of hnRNP U antibody or 
BSA (control) was added to each binding mixture and the mixtures were incubated for additional 
30 minutes. Samples were loaded on a 5% TBE-polyacrylamide gel for electrophoresis 
separation. RNA-protein complexes were then visualized by using Molecular Imager FX (Bio-
Rad) with a 488 nm EX (530 nm BYPASS) laser.  
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2.3 Densitometric analysis of the EMSA supershift 
 The fold-differences in hnRNP U-E3/C9 binding between A549 and HBEpC cells were 
determined by densitometric measurement of the hnRNP U supershift in the scanned EMSA gels 
from three independent experiments (n=4) using ImageJ densitometry software (NIH). 
2.4 Mass spectrometry analysis 
 Analysis of RNA-protein complexes was performed at the Emory University Mass 
Spectrometry Center (Atlanta, Georgia, USA) as previously described (21). Briefly, RNA-
protein complexes retrieved from EMSA were excised from the gel following by in-gel trysin 
digestion. The tryptic mixtures were then analyzed by nano– LC-MS/MS. Nano–LC-MS/MS 
results were obtained by searching through Mascot database (Matrix Science).  
2.5 siRNA transfection 
 A549 or HBEpC cells were transfected with negative control siRNA or hnRNP U 
SMARTpool siRNA or hnRNP R siRNA (Dharmacon) using Dharmafect 1 transfection reagent 
(Dharmacon). Cells (3-4 x 10
5
) were plated in each well of 6-well tissue culture dishes in regular 
growth medium. The following day, cells were plated in Opti-MEM I medium without 
antibiotics/FBS and transfected with 100 nM of siRNA (diluted in 1X siRNA buffer). After 4 
hours of incubation, 0.5 ml Opti-MEM I medium containing 3-fold the normal concentration of 
antibiotics/FBS was added to the 1ml of transfection mixture. Cells in transfection mixture were 
incubated for additional 4 hours before medium was changed to normal growth medium. After 
48 hours, total RNA or protein was collected from the cell lysates.  
2.6 Competitive RT-PCR 
 Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then 
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The 
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reverse transcription reaction products were utilized in PCR for the endogenous caspase-9 
primers (sense primer 5'-CATGCTGGCTTCGTTTCTG-3' and anti-sense primer 5'-
AGGGGCAAACAACAGATGG-3'). PCR was performed in 25 cycles of 94
o
C for 30 seconds, 
58
o
C for 30 seconds and 72
o
C for 1 minute. The final PCR products were resolved on 5% TBE 
polyacrylamide gel, stained with SYBR Gold (Invitrogen) and visualized by using Molecular  
Imager FX (Bio-Rad) with a 488 nm EX (530 nm BYPASS) laser. 
2.7 Quantitative RT-PCR 
 Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then 
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The 
reverse transcription reaction products were utilized for real-time PCR for Casp9a, Casp9b, and 
18s using TaqMan PCR master mix and the Applied Biosystems 7500 Real-Time PCR System. 
Casp9a and 18s q-PCR primers were ID numbers Hs00154261_m1 and Hs99999901_s1. The q-
PCR primers for Casp9b were 5’-GGATTTGGTGATGTCGAGCAG-3′ (forward), 5′-
CATCTGGCTCGGGGTTACT-3′ (reverse) and 5′-TTCCCCTGAAGACGAGTCCCCTGG-3′ 
(probe). The relative amount of Casp9a or Casp9b was normalized to 18s. 
 
2.8 Cell lysate preparation 
 Cell lysates, except for the CIP experiments, were prepared by lysing the cells in NP-40 lysis 
buffer (50 mM Tris-HCl at pH 8.0, 150 mM NaCl, 1% NP-40 and 1X protease/protein 
phosphatase inhibitor cocktail). For cell lysates utilized for the CIP treatment experiments, cells 
were lysed in the same NP-40 buffer as detailed above, but without protein phosphatase 
inhibitors. Lysates were also utilized “fresh” for these experiments (i.e. same day), and not 
stored. 
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2.9 Streptavidin-biotin affinity purification (SBAP) 
 Reaction mixtures (20 µl) containing 10 µg of cell lysates or 4 µg of IgG (control), 40 U 
RNASIN, 11.3 µg tRNAs, 10 mM  HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, 5% 
glycerol and 10 µM biotinylated RNA oligo (C9/E3 WT, C9/E3 Mut1, C9/E3 Mut2, C9/E3 Mut3 
or C9/E3 Mut4) were incubated on ice for 30 minutes. Pre-washed streptavidin-agarose beads 
were then added to the reactions following by 2 hour of incubation with gentle agitation (4°C). 
After incubation, the reactions were washed 3 times with pre-block buffer (100 mM KCl, 20 mM 
Tris-HCl at pH 7.5 and 0.2 mM EDTA) and centrifuged to collect the pellet. The pellet was 
resuspended in Laemmli buffer, dry-boiled for 10 minutes and subjected to western 
immunoblotting. 
2.10 In vitro phosphatase treatment 
 Phosphatase reaction mixtures containing 10 μg cell lysate and 10U calf-intestinal 
phosphatase (CIP) or heat-inactivated CIP (denatured CIP, control) in 1X NEBuffer 3 (New 
England BioLabs) were incubated at 37
o
C. After 1 hour of incubation, 1X phosphatase inhibitor 
cocktail was added to the mixtures. Reaction mixtures were then utilized in EMSA or SBAP for 
RNA-protein binding analysis.   
2.11 Immunoprecipitation (IP) 
 Cells were lysed in 1X IP buffer containing 1% Trition X-100, 150 mM NaCl, 10 mM Tris 
pH 7.4, 1mM EDTA pH 8.0, 0.5% NP-40 and 1X phosphatase/protease inhibitor cocktail. 
Sample lysates (200 μg) were pre-cleared with pre-washed protein G Sepharose beads for 1 hour 
at 4
o
C in gentle agitating condition. After pre-clearing, samples were centrifuged and collected 
from the supernatants. 4 µg of hnRNP U or hnRNP L monoclonal antibody was placed in each 
sample and in 4
o
C for 2 hour with gentle agitation before pre-washed protein G Sepharose beads 
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were added. The following day, the bead complexes were centrifuged, washed extensively with 
1X IP buffer, pelleted by centrifugation, resuspended in Laemmli buffer, dry-boiled for 10 
minutes and subjected to SDS-PAGE/immunoblotting. For IP experiments coupled with CIP 
treatment, cells were lysed in the same IP buffer, but without protein phosphatase inhibitors. The 
IPs were then subjected to CIP treatments as detailed in the above method section.  
2.12 In vitro kinase assay 
 Kinase reaction mixtures (20 μl) containing 80 ng of recombinant hnRNP L, 10 mM  
HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, 5% glycerol, 0.5 mM ATP, 1.25 mM 
glycerol-2-phosphate and 200 ng of AKT2 (Sigma) were incubated at 30
o
C for 30 minutes. 
Reaction mixtures were then utilized in EMSAs for RNA-protein binding analysis or SBAP-
based competitive binding assays.   
2.13 Competitive binding assay 
 Recombinant hnRNP L was subjected to in vitro kinase assay. Kinase reaction mixtures  (20 
µl) were then incubated with 40 U RNASIN, 11.3 µg tRNAs, 10 mM  HEPES, 5 mM DTT, 120 
mM KCl, 3 mM MgCl2, 5% glycerol and 10 μM biotinylated C9/E3 ROs on ice for 30 minutes. 
Pre-washed streptavidin-agarose beads were then added to the reactions following by 2 hour of 
incubation with gentle agitation (4°C). After incubation, the reactions were washed 3 times with 
pre-block buffer (100 mM KCl, 20 mM Tris-HCl at pH 7.5 and 0.2 mM EDTA) and centrifuged 
to pellet the bead complexes. The bead complexes were then incubated with binding mixtures 
(20 μl) containing 10 μg of HBEpC cell lysates, 40 U RNASIN, 11.3 µg tRNAs, 10 mM  
HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl and 5% glycerol for additional 2 hours. After 
incubation, the bead complexes were washed 3 times with pre-block buffer (100 mM KCl, 20 
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mM Tris-HCl at pH 7.5 and 0.2 mM EDTA), pelleted by centrifugation, resuspended in Laemmli 
buffer, dry-boiled for 10 minutes and subjected to SDS-PAGE/immunoblotting.  
2.14 Statistical analysis 
 Statistical differences in the mRNA level between the control and hnRNP U siRNA treated 
cells were determined by a 2-tailed, unpaired Student’s t test. Statistical differences in the 
association of hnRNP U with E3/C9 between A549 and HBEpC cells were determined by one-
sample t-test. P values of less than or equal to 0.05 were considered significant.   
2.15 Antibody information 
The following antibodies were used in western immunoblotting or EMSA/supershift: anti-
caspase-9 (Assay Designs), anti-hnRNP U (Sigma-Aldrich), anti-β-actin (Cell Signaling 
Technology), anti-laminA/C (Cell Signaling Technology), anti-phospho-serine (Cell Signaling 
Technology), anti-phospho-threonine (Cell Signaling Technology), anti-phospho-
(serine/threonine)-AKT substrate (Cell Signaling Technology), AKT2 (Cell Signaling 
Technology), anti-hnRNP L (Santa Cruz Biotechnologies Inc.), anti-phospho-Ser52-hnRNP L 
(custom anti-produced via Genscript Corporation) (21),  horseradish peroxidase-conjugated anti-
rabbit IgG antibody (Cell Signaling Technology) and horseradish peroxidase-conjugated anti-
mouse IgG antibody (Cell Signaling Technology). 
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CHAPTER 3 – RESULTS: 
 REGULATION OF CASPASE-9 SPLICING BY HNRNP U 
 
 
 
 
3.1 Identification of hnRNP U associated with exon 3 of caspase-9 and suppressing the 
formation of the caspase-9b isoform 
 Using EMSA coupled to nanospray LC-MS/MS analysis, four RNA trans-factors, hnRNP L, 
hnRNP A2/B1, hnRNP R and hnRNP U, were previously identified to associate with the purine-
rich sequences in C9/E3 (Table 1.1) (21). hnRNP L was then further characterized to modulate 
the alternative splicing of caspase-9 pre-mRNA as a repressor of the inclusion of the exon 3,4,5,6 
cassette whereas hnRNP A2/B1 did not affect caspase-9 splicing (21). Here, we examine the 
roles of the two other RNA trans-factors, hnRNP U and hnRNP R, on the alternative splicing of 
caspase-9  by employing siRNA technology. Whereas downregulation of hnRNP U reduced the 
endogenous caspase-9a/9b mRNA ratio in both transformed A549 cells and non-transformed 
human bronchial epithelial primary cells (HBEpC) (Fig. 1.4A-D), hnRNP R depletion yielded no 
change in the ratio of caspase-9a/9b mRNA (Fig. 1.4A and B). Importantly, the effect of hnRNP 
U on the mRNA ratio translated to the protein level (Fig. 1.4E). These data indicate that hnRNP 
U inhibits the formation of caspase-9b via suppressing the exclusion of four-exon cassette in the 
mature caspase-9 mRNA.  
 15 
 
Since the two splice variants of caspase-9, caspase-9a and caspase-9b, are generated from the 
same gene and have the same 5’UTR and 3’UTR sequences, the effect of hnRNP U depletion on 
caspase-9a/9b ratio is likely attributable to the regulation of the alternative splicing of caspase-9 
rather than mRNA stability. Indeed, no significant difference in the decay rate (specifically, 
RNA half-life t1/2) of caspase-9a or caspase-9b mRNA was observed after treatment of the 
control versus hnRNP U-depleted cells with actinomycin D (Fig. 1.4F-H). These data “rule out” 
the possibility that hnRNP U represses the production of caspase-9b by stabilizing caspase-9a 
mRNA or destabilizing caspase-9b mRNA. Hence, regulation of the alternative splicing of 
caspase-9 is most likely the mechanism contributing to the observed enhancing function of 
hnRNP U in the inclusion of the four-exon cassette.  
3.2 hnRNP U binds specifically to exon 3 of caspase-9 pre-mRNA 
 The LC-MS/MS results strongly suggested that hnRNP U interacted with C9/E3. To 
determine whether hnRNP U interacts specifically with C9/E3, EMSA coupled with an hnRNP 
U “supershift” was performed (Fig. 1.5A and Table 1.2 for sequences utilized). Indeed, a 
“supershift” was observed after the addition of an anti-hnRNP U antibody indicating that hnRNP 
U is present in the C9/E3-protein complex, and thereby, verifying the LC-MS/MS results (Fig. 
1.5B). Furthermore, this “supershift” was specific for hnRNP U since reduction in levels of 
hnRNP U via siRNA resulted in the loss of the supershift (Fig. 1.5C and D).  
Mutagenesis analysis was employed to further determine/validate the binding site for hnRNP 
U in C9/E3. As shown in Fig. 1.5E and F, the interaction between hnRNP U and C9/E3 was 
completely abolished in one out of four C9/E3 mutations (Mut3). Interestingly, this interaction 
site has been previously identified as the binding site for hnRNP L, a repressor that regulates the 
alternative splicing of caspase-9 (21). Two additional mutations (Mut2 and Mut4) flanking this 
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site also significantly diminished the association of hnRNP U to C9/E3 (Fig. 1.5E and F). These 
findings reveal that hnRNP U specifically interacts with the hnRNP L binding site in C9/E3.  
Also of note, almost a complete loss of protein:RNA complexes was observed with Mut3 in 
accord with our previous findings of hnRNP L binding to this region. These data also suggest 
that hnRNP L, hnRNP U, or both may also target additional RNA trans-factors to exon 3 of 
caspase- 9.   
3.3 Phosphorylation regulates the interaction between hnRNP U and exon 3 of caspase-9 
pre-mRNA 
 Although hnRNP U was expressed at the same level in non-transformed (HBEpC) versus 
transformed (A549) cells (Fig. 1.6A), the association of this RNA trans-factor to C9/E3 in 
HBEpC cells was significantly higher than in A549 cells (Fig. 1.6B and C). Specifically, the 
fold-difference as assayed by EMSA analysis was 1.70 ± 0.18 (mean ± SD) (p < 0.01).  
 Selective phosphorylation of hnRNP U has been reported in a study of Burglund and Larke 
(2009) (3). Thus, we hypothesized that the enhanced binding of hnRNP U to C9/E3 in non-
transformed cells compared to transformed cells was due to the differences in post-translational 
modification, particularly the phosphorylation state. To address this possibility, protein 
phosphatase treatments coupled with RNA binding assays were undertaken. Congruent with our 
hypothesis, the dephosphorylation of NSCLC (A549) cell lysates resulted in significant 
enhancement of the association of hnRNP U to C9/E3 (Fig. 1.6C-E). These findings implicate 
phosphorylation as a regulatory mechanism for hnRNP U-C9/E3 interaction, which may explain 
the differences observed in non-transformed versus transformed cells regarding hnRNP U-C9/E3 
binding. 
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To determine whether the phosphorylation of RNA trans-factors was the mitigating factor in 
modulating the differential association of hnRNP U to C9/E3 in transformed cells versus non-
transformed cells, both A549 and HBEpC cell lysates were subjected to phosphatase (CIP) 
treatment (denatured versus active) in the absence of protein phosphatase inhibitors. 
Dephosphorylation of A549 cell lysates increased the association of hnRNP U to C9/E3 to 
comparable levels of the binding observed in HBEpC cell lysates, whereas the association of 
hnRNP U in the non-transformed cells was unaffected (Fig. 1.6F). These data demonstrated that 
the disparity in hnRNP U binding between transformed and non-transformed cells is due to the 
phosphorylation state of RNA trans-factors (Fig. 1.6G). 
3.4 Inhibition of the AKT pathway promotes the association of hnRNP U with C9/E3 and 
alters the ratio of caspase-9 splice variants 
 The phosphoinositide 3-Kinase/AKT pathway has been reported to modulate the alternative 
splicing of caspase-9 (57), and we hypothesized that this signaling pathway modulates the ability 
of hnRNP U to bind C9/E3. Indeed, treatment the NSCLC cells with AKT1/2 inhibitor increased 
the binding of hnRNP U to C9/E3 in a dose-responsive manner, but did not significantly affect 
its expression level (Fig. 1.7A). Importantly, enhanced association of hnRNP U to C9/E3 by 
AKT inhibitor treatment correlated with the increasing caspase-9a/9b ratio in NSCLC cells (Fig. 
1.7A). In contrast, ectopic expression of constitutively active AKT2 (caAKT2) in non-
transformed HBEpC cells attenuated the binding of hnRNP U to C9/E3, which correlated with a 
decrease in the caspase-9a/9b ratio (Fig. 1.7B).  These data demonstrate that AKT signaling 
regulates the interaction of hnRNP U with caspase-9 pre-mRNA.    
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3.5 The phospho-state of hnRNP U is not affected by AKT inhibition 
 The culmination of our data coupled to reports in the literature of hnRNP U being selectively 
phosphorylated led to the initial hypothesis that the phospho-state of hnRNP U regulates the 
association of the RNA trans-factor to C9/E3 (Fig. 1.7G). In direct opposition to this hypothesis, 
treatment of A549 cells with an AKT inhibitor had no significant effect on the phosphorylation 
state of hnRNP U (Fig. 1.8A) and in vitro phosphatase treatment showed a minor effect on 
serine-phosphorylation (Fig. 1.8B). Importantly, treatment with AKT inhibitor or phosphatase in 
the same condition has been shown to affect the binding of hnRNP U to C9/E3 (figure 1.6D, E, F 
and figure 1.7A), which indicates that phospho-state of hnRNP U does not play an important role 
in regulating the association of the RNA trans-factor with C9/E3.   
3.6 hnRNP L is phosphorylated in an AKT-dependent manner inducing competition with 
hnRNP U for C9/E3 binding 
Since the phospho-state of hnRNP U is not critical to hnRNP U-C9/E3 interaction, we 
hypothesized that the phosphorylation of other regulatory RNA trans-factors modulated the 
ability of hnRNP U to associate with C9/E3. In this regard, hnRNP U shares the same binding 
site as hnRNP L, which has the opposite function in regards to regulating the alternative splicing 
of caspase-9 pre-mRNA. Therefore, we examined the direct binding of recombinant hnRNP L 
purified from non-transformed HEK293 cells to the C9/E3. Interestingly, direct binding of 
recombinant hnRNP L to this purine-rich sequence was not observed by EMSA (Fig. 1.9A, lane 
1), congruent with a report showing the interaction of this recombinant hnRNP L to be specific 
for CA-repeats (51). As caspase-9 RNA splicing is regulated by the phosphorylation of hnRNP L 
(21), we examined whether AKT directly phosphorylates hnRNP L and induces the association 
of the RNA trans-factor with C9/E3. Intriguingly, AKT efficiently phosphorylated hnRNP L, 
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which induced its binding to C9/E3 (Fig. 1.9A). Moreover, inhibition of AKT signaling in 
NSCLC cells directly by AKT inhibitor treatment or indirectly by blocking EGFR activity with 
erlotinib treatment significantly reduced the phospho-state of hnRNP L (Fig. 1.9B). Lastly, 
hnRNP L phosphorylated by AKT interfered with hnRNP U for binding to C9/E3 (Fig. 1.9C) in 
contrast to non-phosphorylated hnRNP L. Taken together, these data demonstrate that the 
phospho-status of hnRNP L is regulated by AKT signaling in NSCLC, which induces the 
association of this RNA trans-factor and restricts the access of the enhancing factor, hnRNP U, 
to C9/E3 (Fig. 1.9D).  
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Table 1.1 RNA trans-factors associated with exon 3 of caspase-9 in NSCLC cells. 
RNA trans-factors 
hnRNP A2/B1 
hnRNP L 
hnRNP R 
hnRNP U 
 
  
 21 
 
Table 1.2 RNA oligos (ROs) utilized in the RNA binding assays (EMSA or SBAP). For mutant 
C9/E3 ROs, the mutated sites are located in the underlined sequences. 
RO code Sequence 
NSC 
C9/E3 WT 
C9/E3 Mut1 
C9/E3 Mut2 
C9/E3 Mut3 
C9/E3 Mut4 
CAGAAUUCGCACGUUACU 
GAGAGUUUGAGGGGAAAU  
CAGAAUUUGAGGGGAAAU 
GAGAGCCCGAGGGGAAAU 
GAGAGUUUCUACUGAAAU 
GAGAGUUUGAGGGUUACU 
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Figure 1.4 hnRNP U, but not hnRNP R, represses the formation of caspase-9b via RNA 
splicing. A549 or HBEpC cells were transfected with control siRNA (100 nM), hnRNP U 
SMARTpool siRNA (100 nM), or hnRNP R siRNA (100 nM) for 48 hours. (A) Total RNA was 
isolated and analyzed by competitive/quantitative RT-PCR for caspase-9 splice variant ratio 
using ratio-based quantitation. (B) Total protein extracts were subjected to 
SDS/PAGE/immunoblotting for hnRNP U, hnRNP R or β-actin. (C) Graphs were created from 
the results in (A). (D) Total RNA isolated from A549 cells transfected with control or hnRNP U 
siRNA was analyzed for relative amount of caspase-9a or 9b mRNA by quantitative RT-PCR 
using the standard curve method and 18s rRNA as a normalizing control. (E) Total protein 
extracts were subjected to SDS/PAGE/immunoblotting for caspase-9 or β-actin. Data are shown 
as means ± SD (n≥4 on at least 2 independent occasions). 
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Figure 1.4 (F) A549 cells were transfected with siRNA as in (A). After 48 hours, cells were 
treated with actinomycin D (5 μg/ml) for 0, 2, 4 or 8 hours. RNA was isolated and relative 
amount of caspase-9a or 9b mRNA (fold change compared to the si-control or si-hnRNP U 
samples at 0 hour) was individually determined by quantitative RT-PCR. (G) Half-life of 
caspase-9a or caspase-9b mRNA was calculated based on the data in (F). (H) Total protein from 
siRNA transfected cells (48 hours) was subjected to SDS/PAGE/immunoblotting for hnRNP U 
or β-actin.  Statistical significance was evaluated by Student’s t test (p < 0.0001, n = 5 on two 
independent occasions).   
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Figure 1.5 hnRNP U binds to exon 3 of caspase-9. (A) Schemetic illustration of caspase-9 pre-
mRNA structure. 18-mer C9/E3 RNA oligos (ROs) used in RNA binding assays are 
corresponding to the purine-rich sequence in C9/E3. (B and C) EMSAs were performed in the 
absence of protein phosphatase inhibitors using 5’-FITC tagged C9/E3 ROs and in the presence 
of IgG (control), A549 cell lysates (B) or lysates from A549 cells transfected with control siRNA 
or hnRNP U SMARTpool siRNA (C). (D) Cell lysate input in (C) was subjected to SDS-PAGE 
and immunoblotted for hnRNP U and β-actin. (E) SBAP was performed using 5’-biotinylated 
non-specific control (NSC), 5’-biotinylated wild-type C9/E3 ROs (C9/E3 WT) or 5’-biotinylated 
mutant C9/E3 ROs (C9/E3 Mut1-4) in the presence of IgG (control) or A549 cell lysates. (F) 
EMSAs were performed as in (C), but using addtitional ROs (5’-FITC tagged C9/E3 Mut1-4). 
Arrows indicate the supershifts obtained by the addition of the hnRNP U antibody. The graphs 
shown in (B), (C), (E) and (F) are representative of n=4 from three independent experiments.  
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Figure 1.6 Phosphorylation regulates the association of hnRNP U with exon 3 of caspase-9. 
(A) hnRNP U is expressed at the same level in both transformed and non-transformed cells. 
A549 (transformed) and HBEpC (non-transformed) cells were cultured under the same condition 
(DMEM media with/without FBS) and confluency. Total protein extracts were subjected to SDS-
PAGE/immunoblotting for hnRNP U and β-actin. (B and C) hnRNP U binds to C9/E3 in higher 
amounts in HBEpCs than in A549 cells. SBAP assays (B) or EMSAs in the presence of protein 
phosphatase inhibitors (C) were performed with either IgG (control) or lysates from A549 or 
HBEpC cells using a 5’-biotinylated or 5-FITC tagged wild-type C9/E3 ROs. (D and E) 
Dephosphorylation increases the binding affinity of hnRNP U to C9/E3. A549 cell lysates 
(“fresh”) were pre-incubated with denatured calf-intestinal alkaline phosphatase (de-CIP) or 
active protein phosphatase (CIP) followed by EMSA (D) in the absence of protein phosphatase 
inhibitors or SBAP (E) to assay the binding with 5’-FITC tagged (D) or 5’-biotinylated (E) 
C9/E3 ROs. IgG was used as a control. (F) Dephosphorylation abolishes the difference between 
A549 versus HBEpC regarding the binding of hnRNP U to E3/C9. A549 (transformed) and 
HBEpC (non-transformed) cells were cultured under the same conditions and confluency, and 
cell lysates were produced. Lysates (“fresh”) were again treated and assayed as in (E). (G) 
Hypothetical model for regulation of hnRNP U/L-C9/E3 interaction by phosphorylation. 
Whereas the phosphorylation event augments the association between hnRNP L and C9/E3, 
phosphorylation of hnRNP U attenuates its binding to C9/E3. The graphs shown in (A), (B), (C), 
(D), (E) and (F) are representative of n=4 from three independent experiments.    
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Figure 1.7 AKT pathway regulates the association of hnRNP U to exon 3 of caspase-9. (A) 
Inhibition of AKT1/2 activity increases the caspase-9a/9b ratio and enhances the binding of 
hnRNP U to C9/E3 in a dose-response manner. A549 cells were treated with 0.1% DMSO 
control or increasing concentrations of the AKT1/2 inhibitor (AKT VIII). Total RNA was 
isolated and analyzed for caspase-9 splice variants by competitive/quantitative RT-PCR. Cell 
lysates from a concomitant experiment were utilized in SBAP to assay the binding of hnRNP U 
to 5’-biotinylated C9/E3 ROs. Cell lysate input for the SBAP was subjected to SDS-PAGE and 
immunoblotted for hnRNP U and β-actin. (B) Overexpression of AKT decreases both caspase-
9a/9b ratio and hnRNP U-E3/C9 association. HBEpC cells were transfected with the control 
adenovirus or the adenovirus expressing constitutive active AKT2 (caAKT2, 25 MOI) for 48 
hours. Total protein or RNA extracts from the transfected cells were then subjected to SDS-
PAGE/immunoblotting or competitive/quantitative RT-PCR. Cell lysates were also generated for 
SBAP to assay the binding of hnRNP U to E3/C9 ROs. The graphs shown in (A) and (B) are 
representative of n=4 from three independent experiments. 
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Figure 1.8 AKT inhibition does not alter the phospho-state of hnRNP U. (A) A549 cells 
were treated with 0.1% DMSO control or AKT1/2 inhibitor (20 µM). Endogenous hnRNP U was 
then immunoprecipitated (IP) and resolved by SDS-PAGE/ immunoblotting for phospho-
serine/threonine or hnRNP U. (B) A549 protein extracts were incubated with denatured or active 
CIP. Endogenous hnRNP U in the resulted protein extracts were immunoprecipitated (IP) and 
resolved by SDS-PAGE/ immunoblotting for phospho-serine/threonine or hnRNP U. The graphs 
shown in (A) and (B) are representative of n=3 from two independent experiments. 
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Figure 1.9 AKT-dependent phosphorylation of hnRNP L leads to the competition with 
hnRNP U for C9/E3 binding. (A) Phosphorylation of hnRNP L by AKT enhances binding to 
E3/C9. Recombinant FLAG-tagged hnRNP L was phosphorylated in vitro using active AKT2 
(denatured AKT2 was utilized as a negative control).  Products from the kinase assay were then 
subjected to SDS-PAGE/immunoblotting for phospho-serine/threonine, or the FLAG tag and 
also utilized in the EMSA to examine the interaction with E3/C9 ROs. (B) AKT or EGFR 
inhibition in NSCLC cells induces a reduction in the phospho-status of hnRNP L. A549 cells 
were treated with either 0.1% DMSO control, AKT inhibitor (20 µM) or erlotinib (EGFR 
inhibitor, 1 µM). Endogenous hnRNP L was immunoprecipitated (IP) from the protein extracts. 
IPed hnRNP L was resolved by SDS-PAGE and immunoblotted with phospho-Ser
52
-hnRNP L or 
hnRNP L antibodies. (C) Exogenous hnRNP L phosphorylated by AKT competes with 
endogenous hnRNP U for binding to E3/C9. Recombinant hnRNP L was incubated with 
denatured or active AKT2 in the in vitro kinase assay and then utilized in the SBAP-based 
competitive binding assay using HBEpC cell lysates and E3/C9 ROs. (D) Model for controlling 
hnRNPU-hnRNP L-E3/C9 interaction by AKT pathway. In the non-transformed cells, the 
recruitment of hnRNP L to E3/C9 is interfered by hnRNP U binding to the same position. 
Through activation of AKT pathway in transformed cells, hnRNP L is phosphorylated, which 
results in the enhanced binding of this splicing repressor to E3/C9. Consequently, the elevated 
levels of hnRNP L associated with E3/C9 prevent the access of hnRNP U to E3/C9 for splice-
enhancing function. The graphs shown in (A), (B) and (C) are representative of n=4 from two 
independent experiments. 
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CHAPTER 4 – DISCUSSION:  
REGULATION OF CASPASE-9 SPLICING BY HNRNP U 
 
 
 
 
 In this study, two additional C9/E3-associated proteins were identified by LC-MS/MS, 
hnRNP R and hnRNP U. Whereas hnRNP R had no effect on caspase-9 splicing, hnRNP U was 
revealed as a splicing enhancer and validated for interaction with C9/E3. To date, little is known 
about the regulatory function of hnRNP U in RNA splicing although it is regarded as an RNA-
binding protein. A recent study suggested that hnRNP U might be a global regulator of 
alternative splicing; however, >90% of reported cases about an RNA splicing change induced by 
hnRNP U down-regulation did not accompany binding to respective mRNA (69). Our findings 
expand the situations where hnRNP U-regulated splicing events are associated with target 
mRNA interactions.    
The precise site for hnRNP U binding on C9/E3 was also examined. Previously, hnRNP U 
has been reported to preferentially bind G/U-rich motifs in RNA (19, 34). In line with these 
reports, hnRNP U was demonstrated to specifically interact with the G-rich sequence, GAGGG 
in C9/E3. Furthermore, mutation of the upstream U-motif (UUUGAGGG) also significantly 
reduced the association of hnRNP U with the C9/E3. Importantly, this sequence has been 
reported as a binding site for hnRNP L. The opposing function of hnRNP U versus hnRNP L and 
the same binding site on C9/E3 suggest regulatory competition between hnRNP U and hnRNP L
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and our data further suggest that the presence of hnRNP U likely restricts the exon-exclusion 
effect of non-phosphorylated hnRNP L. Furthermore, the dramatic loss of protein:RNA complex 
by mutation of this RNA cis-element suggests that hnRNP L and U may target additional RNA 
trans-factors to exon 3. Current experimental directions are focused on determining whether the 
phosphorylation of hnRNP L leads to loss or gain of binding partners, which aid in regulating the 
inclusion/exclusion of the exon 3,4,5,6 cassette. 
The nature of the regulation of the hnRNP U and L competition was also elucidated in this 
study. For example, simple changes in expression of the RNA trans-factors did not account for 
the observed loss of hnRNP U binding in transformed cells. Specifically, the expression of 
hnRNP U and L were not significantly different between non-transformed and transformed cells.  
Previous studies in our laboratory have pointed to the importance of phosphorylation in 
regulating hnRNP L-C9/E3 interaction (21), and hnRNP U has been reported to be selectively 
phosphorylated in response to DNA double-strand breaks (3, 6). Therefore, we hypothesized that 
phosphorylation events might impact the association between hnRNP U and C9/E3. 
Nevertheless, our findings in this study demonstrate that phosphorylation of hnRNP U is unlikely 
to play a role, and the regulatory mechanism is mainly via phosphorylation of hnRNP L. 
Together with the findings that caspase-9a/9b ratio is higher in non-transformed than in 
transformed cells (21, 57) and the enhanced association of hnRNP U in non-transformed cells, 
these data extend the mechanistic insights into the dysregulation of caspase-9 splicing in 
transformed cells. In this paradigm, certain survival/oncogenic kinases are activated and 
phosphorylate hnRNP L in transformed cells. As a result, the hnRNP L-C9/E3 interaction and 
subsequent splice-repressing function is promoted while hnRNP U is prevented from binding and 
competing with hnRNP L (Fig. 1.9D). Therefore, the exclusion of four-exon cassette is favored 
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shifting the alternative splicing of caspase-9 to the lower caspase-9a/9b ratio observed in NSCLC 
cells.  
Since the enhanced exclusion of exon 3,4,5,6 cassette has been linked to phosphorylation 
events modulated by phosphoinositide 3-kinase/AKT pathway (Shultz 2010), this cell-survival 
regulatory pathway likely mediates the phosphorylation of hnRNP L and subsequently the 
competitive interaction between hnRNP L and hnRNP U to C9/E3. Indeed, inhibition of AKT 
signaling in transformed cells augmented hnRNP U-C9/E3 binding, and the enhanced binding to 
the C9/E3 were correlated perfectly with alteration in caspase-9 splice variant ratio. Hence, the 
AKT pathway regulates the alternative splicing of caspase-9 via hindering the interaction 
between hnRNP U and C9/E3 and subsequently suppressing its splice-enhancing function. Our 
study also demonstrates that hnRNP L is a direct substrate for AKT, and thus, AKT may be 
directly influencing the alternative splicing of caspase-9 via hnRNP L. Direct phosphorylation of 
hnRNP L by AKT is not heretical as AKT has been shown to directly phosphorylate SRSF1 
(SRp30a or ASF/SF2), another RNA trans-factor known to regulate the alternative splicing of 
caspase-9 (57).   
In regards to SRSF1 and caspase-9 RNA splicing, the presented study fills a missing “gap” in 
our knowledge of how the exon 3,4,5,6 cassette is regulated. Previously, we reported that the 
phosphorylation of SRSF1 on novel phosphorylation sites flanking the RS domain were partially 
required for AKT activation to exclude the exon 3,4,5,6 cassette (57). Specifically, we showed 
that a phospho-mimic of SRSF1 could only partially block the exclusion of the exonic cassette of 
caspase-9 pre-mRNA induced by an AKT inhibitor. This study now places hnRNP L 
phosphorylation and subsequent hnRNP U displacement from exon 3 as the plausible missing 
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mechanism by which AKT activation maximally induces the exclusion of the exon 3,4,5,6 
cassette. 
One of the more intriguing findings is the observation that phosphorylation of hnRNP L 
induces the association of the RNA trans-factor with a non-standard binding site. Numerous 
reports in the literature have demonstrated that hnRNP L prefers CA-repeats. Indeed, we initially 
found that recombinant hnRNP L did not bind the purine-sequence in-line with previous reports; 
however, hnRNP L can be modulated to associate with different sequence specificity by 
phosphorylation. Our data, therefore, suggest that hnRNP L may have both constitutive roles in 
RNA splicing as well as activated roles in modulating a subset of splicing events. How 
phosphorylation would change the sequence specificity of an RNA trans-factor has not been 
described, but possibly one or more qRRM motifs could be “unmasked” by an intra-molecular 
change in the structure of the RNA trans-factor stimulated by phosphorylation. This mechanism 
is plausible as hnRNP K, a related RNA trans-factor, has been reported to have a qRRM that 
does not recognize the standard GC-rich RNA sequence (46). Overall, phosphorylation may be a 
key regulatory step in activating RNA splicing factors to induce specific RNA splicing events 
(e.g. caspase-9 RNA splicing) in response to external stimuli outside of their roles in constitutive 
RNA splicing.  
In conclusion, our presented work implicates hnRNP U as a limiting factor for caspase-9b 
formation, which has been previously demonstrated to enhance the anchorage-dependent growth 
and tumorigenic capacity of non-small cell lung cancer (NSCLC) cells (21). Moreover, cascape-
9b is not significantly expressed in non-transformed cells (21), and the induction of caspase-9b 
expression is due to activation of hnRNP L via phosphorylation to compete/inhibit hnRNP U 
association with C9/E3. Therefore, targeting the phosphorylation of hnRNP L by specific kinase 
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inhibitors to further augment the formation of apoptotic caspase-9a over anti-apoptotic caspase-
9b would be an attractive cancer-specific approach for treatment of NSCLC (50).     
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CHAPTER 5 – INTRODUCTION:  
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY 
 
 
 
 
5.1 Caspase-9b  
As presented in 1.3, the alternative splicing of caspase-9 leads to the formation of two splice 
variants and two corresponding isoforms, caspase-9a and caspase-9b. Lacking the catalytic site 
but still containing the CARD domain in the structure confers caspase-9b the anti-apoptotic 
capability (55, 59). Specifically, caspase-9b can bind to Apaf-1 via the CARD domain and 
competes with caspase-9a for Apaf-1 association. Protection against apoptosis is also the only-
known function of caspase-9b. Recently, caspase-9b has been reported to enhance the anchorage-
independent growth and tumorigenic capacity of NSCLC cells (21), which indicates that besides 
inhibiting apoptosis, caspase-9b may have activating roles in certain survival/oncogenic 
pathway(s). Understanding the mechanisms of how caspase-9b augments the anchorage-
independent growth and tumorigenic capacity of NSCLC cells would have significant 
contribution to therapeutic development against lung cancer based on targeting caspase-9b. 
5.2 NF-κB signaling: the canonical and non-canonical pathway 
NF-κB refers to a family of transcription factors, Rel family, which plays important roles in 
various biological processes including inflammation, immune response, cell growth control, 
apoptosis and development (24, 64). In mammalian cells, five NF-κB 
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proteins have been identified: RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 
(p100/p50). These NF-κB proteins form different homodimeric or heterodimeric complexes that 
can enter the nucleus, bind to the κB-enhancer sites and trans-activate numerous responsive 
genes. For structural comparison, all five NF-κB proteins share a unique N-terminal Rel 
homology domain (RHD) required for the formation of hetero- or homo-dimers and DNA 
binding. However, only RelA, RelB and c-Rel has C-teminal transactivation domain (TAD), 
which can activate the dimeric transcription factor complexes formed with p52 or p50. Since p52 
and p50 both lacks TAD, their homo-dimers act as transcription repressors.  
NF-κB dimers are normally sequestered in the cytoplasm by a family of inhibitors, 
comprising IκB-α, IκB-β, IκB-γ, IκB-ε, NF-κB1 p105 (precursor) and NF-κB2 p100 (precursor). 
The NF-κB inhibitors mask the nuclear localization signals (NLS) within NF-κB proteins and 
capture them in the cytoplasm. The precursor NF-κB1and NF-κB2, p105 and p100, have the 
IκB-like ankyrin-repeat domain, which thereby functions as NF-κB inhibitors. Proteosomal 
processing of p105 and p100 not only generates the active NF-κB1 p50 and NF-κB2 p52 but also 
abolishes the IκB-like action of the 
precursor proteins. 
There are two main arms of the NF-κB signaling, the canonical and noncanonical NF-κB 
pathway (Fig. 2.1). The canonical NF-κB pathway is activated by a broad range of stimuli such 
as inflammatory cytokines, lipopolysaccharides (LPS), growth factors or antigen receptors. The 
limiting step in the canonical NF-κB pathway is the inducible degradation of IκB proteins, 
particularly IκBα, which leads to nuclear transport of various NF-κB complexes, predominantly 
the RelA-containing dimer. Upon canonical NF-κB activation, IκB-α is phosphorylated by the 
IκB kinase (IKK), which is a trimeric complex 
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composed of two catalytic subunits, IKK-α and IKK-β, and a regulatory subunit, IKK-γ (or NF-
κB essential modulator, NEMO). Phosphorylation of IκB-α results in its poly-ubiquitination and 
proteasome-mediated degradation. The non-canonical NF-κB pathway is signaled through 
particular TNF receptor family members that bind to the TNF receptor associated factors TRAF2 
and/or TRAF3, such as LTβR, CD40, CD27, CD30, BAFF-R and RANK. Activation of the non-
canonical pathway relies on NIK and IKKα-mediated phosphorylation and processing of NF-κB2 
p100 precursor to p52, which then undergoes nuclear translocation of p52-containing dimers. 
5.3 The roles of NF-κB activation in lung tumorigenesis and tumor progression 
 NF-κB is an inducible member of Rel family of transcription factors that regulate the 
expression of more than 200 genes, many of which encode for anti-apoptotic proteins such as 
Bcl-xL, cIAP1/2, A20, TRAF-2 and c-FLIP (32), regulatory factors in cell cycle control such as 
cyclin D (26) and GADD45 (10), angiogenesis factors such as VEGF (vascular endothelial 
growth factor), TNFα and MMPs (matrix metalloproteinases) (22, 42) and regulatory factors 
involved in cell migration and adhesion such as VCAM-1 (vascular cell adhesion molecule-1), 
ICAM-1 (intercellular adhesion molecule-1), CXCR4 (chemokine receptor) and uPA (serine 
protease urokinase-type plasminogen activator) (22, 42). Therefore, NF-κB signaling may be 
utilized by cancer cells to survive, proliferate, invade and metastasize. In fact, NF-κB pathway is 
constitutively activated in a variety of cancers, including prostate, breast, cervical, pancreatic and 
lung cancer (31, 40). Tumor samples from lung cancer patients present high levels of NF-κB 
activation in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (29, 
31). Furthermore, it has been reported that NF-κB activation contributes to lung tumor formation 
and progression in mouse models (2, 14, 47) and also plays important roles in the invasion of 
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lung cancer cells (11, 27). In sum, the correlation between lung cancer development and NF-κB 
activation has been well-established.  
5.4 Targeting NF-κB signaling for NSCLC treatment 
 Anti-cancer drugs have been showed to induce NF-κB activation in cancer cells, which 
contributes to chemoresistance in these cells (30, 52, 66). Hence, NF-κB pathway is now an 
attractive target for therapeutic design to sensitize cancer cells to apoptosis induced by chemical 
therapy or to limit cancer invasion and metastasis. Current NF-κB inhibitors include natural or 
synthesized compounds that target NF-κB signaling directly by targeting various 
components/steps in the NF-κB pathway (e.s., activation of IKK, degradation of IκBα, nuclear 
translocation and DNA binding of NF-κB complexes) or indirectly by targeting factors that 
suppress/activate the NF-κB pathway (e.s., tumor suppressor p53, aurora kinases, heat shock 
protein 90) (12). Several NF-κB inhibitors that sensitize lung cancer cells to chemical therapy 
and radiation treatment are listed in Table 2.1. Interestingly, RNA aptamer targeting NF-κB1 
p50 has been shown to inhibit NF-κB activation in NSCLC cells A549 and sensitize the cells to 
apoptosis (48, 49). Nevertheless, there are concerns about using NF-κB inhibitors in cancer 
therapy: 1) suppression of NF-κB signaling may impair immunity since NF-κB pathway plays 
crucial roles in both innate and adaptive immunity; 2) the efficacy of NF-κB inhibitors varies in 
different cells and tissues; and 3) NF-κB inhibitors may have off-target effects (e.s., inhibition of 
NF-κB by proteasome inhibitors may affect the turnover of other proteins outside of NF-κB 
pathway). Tremendous efforts have been made to develop an effective and selective NF-κB 
inhibitor that can be used as a single or adjuvant agent to treat NSCLC.  
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5.5 Specific aims of the study  
The previously observed promoting effect of caspase-9b on the anchorage-independent 
growth and tumorigenicity of NSCLC cells (21) leads to our hypothesis that caspase-9b activates 
certain survival/oncogenic pathway(s) besides inhibitory roles on caspase-9a activation. In this 
study, we found the survival/oncogenic NF-κB pathway as the potential target of caspase-9b. We 
also determined the mechanistic roles of caspase-9b on each arm of the NF-κB pathways, the 
canonical and non-canonical arm. We further examined the biological relevance of the functions 
of caspase-9b in the NF-κB pathway, particularly the effects on cell survival, anchorage-
independent growth and tumorigenicity of NSCLC cells.    
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Table 2.1 NF-κB inhibitors sensitizing lung cancer cells to chemotherapeutics or ionizing 
radiation (12) µ 
NF-κB inhibitors Correlative chemotherapeutics or 
ionizing radiation  
Genistein Cisplatin, docetaxel 
Embelin Paclitaxel 
Curcumin Vinorelbine 
Knockdown of p65  Adriamycin 
Expression of IκBα Paclitaxel 
Expression of mutant IκBα  
(super repressor) 
Cisplatin, gemcitabline, adriamycin, 
etoposide 
β-lapachone, nimesulide and MG132, 
resveratrol, knockdown of TRAF2 
Ionizing radiation 
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Figure 2.1 The canonical and non-canonical pathway in the NF-κB signaling. The limiting 
step in the canonical pathway is the proteosome-mediated degradation of IκB proteins, which 
allows the nuclear translocation of p65-containing complexes. In the non-canonical pathway, 
NF-κB activation is normally controlled by ubiquitination-mediated destabilization of NIK 
protein, which prevents the proteosomal processing of the NF-κB2 p100 to p52 and further 
inhibits the nuclear transport of p52-containing complexes.   
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CHAPTER 6 – MATERIALS AND METHODS:  
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY 
 
 
 
 
6.1 Cell culture  
 A549 and H838 lung adenocarcinoma cells were cultured in 50% DMEM and 50% RPMI 
medium with 10% (v/v) FBS (Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin 
sulfate (Invitrogen). HEK 293 cells were cultured in DMEM medium with 10% (v/v) FBS 
(Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin sulfate (Invitrogen). Human 
bronchial epithelial primary cells (HBEpC) were cultured in Bronchial/Tracheal Epithelial Cell 
Growth medium (Cell Applications). All cells were maintained at less than 80% confluency 
under standard incubator conditions.   
6.2 siRNA transfection  
 A549, H838 or HBEpC cells were transfected with control siRNA or target siRNA for 
caspase-9a, caspase-9b or c-IAP1 (Dharmacon) using Dharmafect 1 transfection reagent 
(Dharmacon). Sequences of control or target si-RNA for caspase-9a or caspase-9b were listed in 
Table 2.2. Cells (3-4 x 10
5
) were plated in each well of 6-well tissue culture dishes in regular 
growth medium. In the following day, cells were plated in Opti-MEM I medium without 
antibiotics/FBS and transfected with 50 nM (for c-IAP1) or 100 nM (for caspase-9a or caspase-
9b) of siRNA (diluted in 1X siRNA buffer). In the next day, medium was changed to normal 
growth medium. After 24 hours, cells were collected for further analysis or transfected with 
adenovirus for additional 24 hours.  
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6.3 Next-Generation RNA Sequencing and Expression Analysis 
RNAs extracted from the cells using the RNeasy Mini Kit (Invitrogen) were sent to Nucleic 
Acids Research Facilities, Virginia Commonwealth University, for Next-Generation Sequencing 
(deep RNA sequencing). FASTQ files were analyzed using the Galaxy software and Tuxedo 
protocol (62). Quality control of fragments was carried out using the FASTQC tool. Fragments 
were mapped to a reference genome using Tophat, and merged using Cuffmerge. BAM files 
were generated using Cufflinks and statistically significant transcripts were identified using 
Cuffdiff. Resulting files were analyzed using Ingenuity Pathway Analysis in order to identify 
differentially regulated pathways. 
6.4 Plasmid transfection and selection of stable cell lines 
Cell lines were transfected with plasmid vectors using Effectene Transfection Reagent 
(Qiagen Inc.) following the manufacturer’s protocol. Briefly, cells were plated at approximately 
40-60% confluency in 6-well plates or 100 mmm tissue culture dishes. The following day, cells 
were transfected with plasmid constructs. After 24 hours of standard incubation, cells were used 
in preparation of the protein extracts for Western immunoblotting or cell lysates for 
immunoprecipitation (IP)/co-immunoprecipitation (coIP).  
For stable cell selection, cells were plated at 1.5x10
4
 cells in each well of 6-well plates. The 
following day, cells were transfected with 1ug of plasmid using Effectene Transfection Reagent 
(Qiagen Inc.). Cells were passaged into zeocin selection medium 24 hours after transfection and 
consistently treated with zeocin for 2 weeks.  
6.5 Nuclear and cytoplasmic extraction 
 Cytoplasmic and nuclear extracts were separated and prepared from cells using NE-PER 
Reagents (Thermo scientific) following manufacture’s protocol. For preparation of nuclear 
extract further used in DNA binding enzyme-linked immunosorbent assay (ELISA), the nuclear 
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pellet was resuspended in complete lysis buffer provided by the TransAM® NFκB p52/p65 
ELISA Kits (Active Motif) instead of the NE buffer in the NE-PER Reagents (Thermo 
scientific). 
6.6 Quantitative RT-PCR 
 Total RNA was extracted from the cells using the RNeasy Mini Kit (Invitrogen) and then 
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase Kit (Invitrogen). The 
reverse transcription reaction products were utilized for real-time PCR for BIRC5, CXCR4, IRF3 
and 18s using TaqMan PCR master mix and the Applied Biosystems 7500 Real-Time PCR 
System. ID numbers for BIRC5, CXCR4, IRF3 and 18s q-PCR primers (Applied Biosystems) 
were listed in Table 2.3. The relative amounts of BIRC5, CXCR4 and IRF3 were normalized to 
18s. 
6.7 DNA binding enzyme-linked immunosorbent assay (ELISA) for activated NFkB 
transcription factors 
 DNA-binding capacity of NF-κB p52- or p65-containing complexes were evaluated by using 
TransAM® NFκB p52/p65 ELISA Kits (Active Motif) and following the manufacturer’s 
protocol. 5 µg of nuclear extract (in complete lysate buffer) was used for each well of the 96-
well plate in which oligonucleotides containing NF-κB consensus binding site had been 
immobilized. The specific competitors (SC), which are the wild-type consensus oligonucleotides, 
and the non-specific competitors (NSC), which are the mutated consensus oligonucleotides, were 
utilized as the control for the specificity of the binding to the NF-κB consensus binding 
sequence. The Jurkat or Raji nuclear extract was used also as the positive control for p65 or p52 
activation, respectively. 
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6.8 Immunoprecipitation (IP) and coimmunoprecipitation (coIP) 
  Cells were lysed in 1X coIP buffer containing 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM 
EDTA pH 8.0, 0.5% NP-40 and 1X phosphatase/protease inhibitor cocktail. Cells used for 
further immunoprecipitation of NIK were treated with 10 μM of proteasome inhibitor MG-132 
for 1 hour before being lysed. For RIP, NIK or c-IAP1 immunoprecipitation/co-
immunoprecipitation, 2 µl of RIP1, NIK or c-IAP1 monoclonal antibody was placed in each 
sample (0.5-1 mg of total proteins) for 4-5 hours at 4
o
C with gentle agitation before 15 µl of pre-
washed protein A/G magnetic beads (Thermo scientific) were added and incubated at room 
temperature for 10 minutes with gentle agitation. The bead complexes were washed 3 times with 
1X coIP buffer, pelleted, resuspended in Laemmli buffer, incubated at room temperature for 10 
minutes and the resulting supernatant were subjected to SDS-PAGE/immunoblotting. For myc or 
FLAG co-immunoprecipitation, 15ul of pre-washed anti-FLAG M2 magnetic beads (Sigma) or 
anti-Myc tag magnetic beads (Origene) were placed in each cell lysate sample for 3-4 hours at 
4
o
C with gentle agitation. The bead complexes were washed 3 times with 1X coIP buffer, 
pelleted and incubated with 60-80 μl of myc or 3X FLAG peptide (Sigma) solution for 45 
minutes at 4
o
C to elute the myc/FLAG fusion proteins. Final concentration of peptides in elution 
solution was 0.5 µg/ul in PBS with 1X phosphatase/protease inhibitor cocktail. The eluates were 
directly used in the in vitro ubiquitination assay or subjected to SDS-PAGE/immunoblotting.    
6.9 Cell survival assay (colony formation assay) 
 Cells were trypsinized and 150 cells were plated in each well of the 6-well plates in normal 
growth medium (cells were plated on 3 wells for each occasion). Cells were incubated under 
standard incubator conditions for 10-14 days before the colonies were fixed with methanol and 
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stained with 0.05% crystal violet solution for 10 minutes. Then visually stained colonies were 
counted. 
6.10 Colony formation assay in soft-agar 
 Cells were trypsinized and a total of 2,000 cells in 1ml top agar (normal growth media 
containing 0.35% agarose) were plated over 1.5 ml base agar layer (normal growth media 
containing 0.6% agarose) in each well of 6-well plates (cells were plated on 3 wells for each 
occasion). Cells were incubated under standard incubator conditions for 4 weeks before the 
colonies were stained with 0.005% crystal violet for 1 hour. Stained colonies with diameters 
larger than 100 μm were counted under a dissecting microscope. For colony size distribution, 
images from each well of the soft-agar plates were taken and image J program was used to 
calculate the average size of colonies.  
6.11 In vitro ubiquitination assay  
 FLAG tagged cIAP1 or myc tagged wild-type/mutant caspase-9b was purified by 
immunoprecipitation of FLAG or myc fusion proteins from HEK 293 cells transfected with 
FLAG tagged cIAP1 plasmids or myc tagged wild-type/mutant caspase-9b plasmids for 24 hours 
in normal growth medium and placed in serum-free medium  for additional 6 hours. Purified 
products of FLAG or myc immunoprecipitation from HEK 293 cells transfected with parental 
empty plasmids were utilized also as the negative control.  In vitro ubiquitination reactions were 
performed at 37
o
C for 1 hour. The reaction mixtures (20 µl) included 50 nM E1 (Boston 
Biochem E-305), 0.5 µM Ubc H5a E2 (E2-616), 1 μl FLAG tagged cIAP1 as E3 ligase or FLAG 
negative control, 8 μl myc-tagged wild-type/mutant caspase-9b or myc negative control, 100 ng 
recombinant tagged RIP1 (Abcam), 10 µM ubiquitin (Boston Biochem), 5 mM ATP, 50 mM 
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Tris 7.5, 5 mM MgCl2 and 2 mM DTT. After incubation time, the product mixtures were 
analyzed by Western immunoblotting. 
6.12 Animals and tumor models 
Six-week-old male C.B-17 SCID (IcrHsd-Prkdc
scid
) mice were purchased from Harland. 
Animal experiments were conducted at Virginia Commonwealth University. The research 
protocol (protocol number AD10000534) was approved by the VCU IACUC involving animal 
care in accordance with the US Department of Agriculture (USDA) Animal Welfare 
Regulations, the Public Health Service Policy on the Humane Care and Use of Laboratory 
Animals, and the US Government Principles for the Utilization and Care of Vertebrate Animals 
Used in Testing, Research, and Training. VCU is in compliance with all provisions of the 
Animal Welfare Act and other federal statues and regulations relating to animals. VCU is 
registered under the Animal Welfare Act as a class R research facility with the USDA Animal 
and Plant Health Inspection Service (APHIS) Animal Welfare (registration number 52-R-0007). 
The Office of Laboratory Animal Welfare (OLAW) approved the VCU Animal Welfare 
Assurance in compliance with the Public Health Service Policy (assurance number A3281-01). 
The SCID mice were acclimatized to the VCU Medical School Animal Facility for a week 
before they received injections of cancer cells: 1.1x10
6
 A549 human NSCLC cells were 
resuspended in 100 μl DMEM and injected subcutaneously into the right hind flank. Tumors 
were allowed to develop for up to 4 weeks and tumor size was measured every week by using a 
caliper. After 4 weeks, mice were sacrificed and tumors were extracted and weighed.  
6.13 Statistical analysis 
 Statistical differences between 2 objects were determined by a 2-tailed, unpaired Student’s t 
test. Statistical differences among more than 3 objects were evaluated by one-way ANOVA 
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followed by a Tukey’s HSD test. p values of less than or equal to 0.05 were considered 
significant.   
6.14 Adenovirus information 
 Adenovirus control (Vector Biolabs, catalog number 1300), adenovirus expressing IκB-α 
(Vector Biolabs, catalog number 1504) or dominant negative IκB-αS (Vector Biolabs, catalog 
number 1028) were used at 20-50 MOI. Adenovirus control or expressing caspase-9b were used 
at 5 MOI for HBEpC cells, at 10 MOI for H838 cells and at 20-50 MOI for A549 cells. Higher 
virus titer was used in A549 cells to obtain relatively the same level of protein expression. 
6.15 Antibody information 
 The following antibodies were used in western immunoblotting, immunoprecipitation (IP) or 
co-immunoprecipitation (co-IP): anti-caspase-9 (Assay Designs), anti-p65 (Cell Signaling 
Technology), anti-NF-κB2 (Cell Signaling Technology), anti-IκB-α (Cell Signaling 
Technology), phospho-IκB-α (Cell Signaling Technology), anti-β-actin (Sigma), anti-laminA/C 
(Cell Signaling Technology), anti-α-tubulin(Cell Signaling Technology), anti-NIK (Cell 
Signaling Technology), anti-RIP1 (Cell Signaling Technology), anti-ubiquitin (Cell Signaling 
Technology), anti-cIAP1 (Cell Signaling Technology), anti-Apaf1 (Cell Signaling Technology), 
anti-FLAG (Sigma), anti-myc (Cell Signaling Technology),  horseradish peroxidase-conjugated 
anti-rabbit IgG antibody (Cell Signaling Technology) and horseradish peroxidase-conjugated 
anti-mouse IgG antibody (Cell Signaling Technology) 
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Table 2.2 Control si-RNA for caspase-9a or caspase-9b, caspase-9a si-RNA and caspase-9b si-
RNA utilized in the study.   
 
si-RNA name Sequence 
 Random control  
 Mutant caspase-9a control,  
a mixture of 3 siRNA: 
o Mutant caspase-9a 1 
o Mutant caspase-9a 2 
o Mutant caspase-9a 3 
 Mutant caspase-9b control 
 Caspase-9a,  
a mixture of 3 siRNA: 
o Caspase-9a 1 
o Caspase-9a 2 
o Caspase-9a 3 
 Caspase-9b 
GGAAUUCCAUCUAGCUCAAACUU 
 
ACCAGUGGCACUACUGCGGUUUU 
CAUCAGAAGAACUGCGGUGAGUU 
CACUAGACGCGUGAGGCCAGGUU 
GUAUAGGACAUCACGACGAUAUU 
 
AACAAUGUGAACUUCUGCCGUUU 
AAUGUGAACUUCUGCCGUGAGUU 
AACUUCUGCCGUGAGUCCGGGUU 
GAUUUGGUGAUGUCGAGCAUUUU 
 49 
 
Table 2.3 qPCR primers specific for NF-κB target genes.  
 
 
  
Gene ID number 
BIRC5 
CXCR4 
IFR3 
18S 
Hs04194392_s1 
Hs00607978_s1 
Hs01547283_m1 
Hs99999901_s1 
 50 
 
CHAPTER 7 – RESULTS:  
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY 
 
 
 
 
7.1 Identification of NF-κB as the signaling pathway of caspase-9b target 
Until now, the only-known function of caspase-9b is protection against apoptosis by 
inhibition of caspase-9a processing (44, 48). Since expression of caspase-9b has previously 
demonstrated to augment tumorigenicity of NSCLC cells, caspase-9b expression might have a 
“gain of function” phenotype or in other words, activate survival/oncogenic pathways outside of 
its inhibitory effect on caspase-9a function. Therefore, high throughput next-generation 
sequencing (deep RNA sequencing) has been performed to identify cell signaling pathways as 
plausible targets of caspase-9b and deep RNA sequencing analysis has revealed a potential link 
between caspase-9b and the NF-κB pathway. Specifically, down-regulation of caspase-9b affects 
expression of various genes, which have been shown in literature to be related to the up-stream 
or down-stream of the NF-κB pathway (figure 2.2 and table 2.4). Furthermore, nearly 40% of 
these genes are NF-κB responsive genes (table 2.5). The finding of NF-κB as a potential pathway 
of caspase-9b target suggests that caspase-9b might regulate the survival/oncogenic NF-κB 
pathway and affecting the NF-κB pathway might contribute to caspase-9b-mediated 
enhancement of tumorigenic capacity of NSCLC cells.   
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7.2 Caspase-9b activates the canonical and inhibits the noncanonical NF-κB pathway 
The roles of caspase-9b in the NF-κB signaling were further validated. In the NF-κB 
pathway, p65- or p52-containing complexes are the dominant complexes in the canonical or 
noncanonical arm and activation of the canonical or noncanonical arm leads to the nuclear 
transport of p65 or p52 complexes, respectively. As shown in figure 2.3A and B, knocking down 
of caspase-9b resulted in less p65 but more p52 translocated into the nucleus and expressing 
caspase-9b increased the nuclear p65 level but decreased the level of nuclear p52. In correlated 
with the nuclear translocation, caspase-9b impacts, in a contrasting manner, the expression of the 
canonical versus non-canonical NF-κB target genes (figure 2.3C and D). More p65 or less p52 in 
the nucleus of the caspase-9b-reduced cells also leads to more p65 or less p52 binding to DNAs 
containing NF-κB responsive sites (figure 2.3E and F). Together, these findings indicate the 
opposite roles of caspase-9b in two arms of the NF-κB pathway, activating the canonical and 
inhibiting the noncanonical arm. 
The limiting step in the canonical NF-κB pathway is the phosphorylation-mediated turn-over 
of IκB proteins, particularly IκB-α, whereas activation of the noncanonical pathway relies on 
stabilization of NIK and processing of NF-κB2 p100 precursor to p52. Hence, NF-κB2 p100 
processing and the level of IκB-α and NIK were evaluated when caspase-9b is up- or down-
regulated. As a result, caspase-9b was shown to dramatically promote the the processing of NF-
κB2 p100, phosphorylation and degradation of IκB-α (figure 2.4A and B). Caspase-9b was also 
shown to impact the ubiquitination and turn-over of NIK (figure 2.4C, D and E). Since it has 
been reported that NIK is tightly controlled by ubiquitination- and proteasome-mediated 
degradation (41), the observed increase in NIK level (figure 2.4C and D) and decrease in NIK 
ubiquitination (figure 2.4E) as caspase-9b is down-regulated supports our model where caspase-
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9b prevents the noncanonical NF-κB activation by elevating the ubiquitination and degradation 
of NIK. Caspase-9b down-regulation not only affected NIK ubiquitination, it also decreased 
RIP1 ubiquitination (figure 2.4E). RIP1 is a crucial factor in the NF-κB signaling, of which 
ubiquitination has been known to positively regulate the canonical NF-κB pathway (15, 33, 67), 
contrary to ubiquitination of NIK and consequent non-canonical NF-κB repression (41). 
Therefore, these findings further solidify the dual actions of caspase-9b in the NF-κB signaling: 
on one hand, caspase-9b stimulates RIP1 ubiqutination and enhances phosphorylation-mediated 
degradation of the IκB-α, freeing p65-containing complexes to translocate into the nucleus for 
gene transcription; on the other hand, caspse-9b facilitates ubiquitination-mediated degradation 
of NIK and thereby prevents the processing and nuclear transport of the NF-κB2, which then 
keeps the non-canonical NF-ΚB in an off-state.  
7.3 Caspase-9b enhances the survival and anchorage-independent growth (AIG) capability 
of NSCLC cells by activation of the canonical NF-κB pathway 
Caspase-9b expression has been demonstrated to promote the anchorage-independent growth 
(AIG) and tumorigenic capacity in NSCLC cells (21). In accordance with the literature, down-
regulation of caspase-9b resulted in a decrease of cell survival and stable expression of caspase-
9b increased the survival of NSCLC cells (figure 2.5A and B). Due to the activating roles of 
caspase-9b in the oncogenic/survival NF-κB pathway, i.e. the canonical pathway, it is likely that 
activation of the canonical NF-κB contributes to the enhancement of cell survival by caspase-9b. 
In order to address that hypothesis, the NF-κB suppressor IκB-α or the dominant-negative 
suppressor (or super repressor), IκB-αS, was expressed in the NSCLC cells followed by 
expression of caspase-9b. Repression of the canonical NF-κB by expression of the suppressor or 
super suppressor both led to a significant decrease in cell survival and only the suppressing effect 
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of the IκB-α on the survival was rescued by caspase-9b expression (figure 2.5C). Additionally, 
caspase-9b expression enhanced the degradation of IκB-α but had no effect on IκB-αS level 
(figure 2.5C), which might explain the rescue of cell survival by caspase-9b expression only 
toward IκB-α expression. Another approach was utilized to determine the biological relevance of 
the NF-ΚB activating roles of caspase-9b, particularly focusing on the cell survival and AIG: the 
suppressor or super suppressor was expressed in the control cells or cells stably expressing 
caspase-9b. For the control cells, expression of either suppressor IκB-α or super suppressor IκB-
αS resulted in a decrease of colony formation in both conditions, with or without soft-gar but for 
the cells stably expressing caspase-9b, only expression of the non-degradable IκB-αS reduced the 
number of colonies formed (figure 2.5D). Importantly, cells stably expressing caspase-9b had 
lower level of IκB-α but the same level of IκB-αS compared to control cells (figure 2.5D), which 
is in agreement with all findings above and the hypothesis that caspase-9b augments the cell 
survival and AIG by facilitating degradation of IκB-α and consequent canonical NF-κB 
activation. 
7.4 cIAP1 plays critical roles in caspase-9b-mediated NF-κB activation/inhibition  
The roles of caspase-9b in both canonical and non-canonical NF-κB pathway give rise to a 
possibility that caspase-9b might interact with certain regulatory factors that mediate the cross-
talk between two arms of the signaling pathway.  In this regard, cellular inhibitors of apoptosis 
(cIAPs) are of interest since c-IAP proteins have been known to have functions in both canonical 
and non-canonical pathway (5, 28, 44, 64, 65, 71). Validated by our study, down-regulation of c-
IAP1 had similar effects as caspase-9b on the NF-κB signaling. c-IAP1 down-regulation 
increased the processing of the NF-κB2 p100 to p52 and the level of both NIK and IκB-α (figure 
2.6A). Furthermore, c-IAP1 depletion altered the level of nuclear p65 and p52, specifically 
 54 
 
decreased p65 and increased p52 level (figure 2.6B). Down-regulation of c-IAP1 also reduced 
the ubiquitintation of RIP1 and NIK (figure 2.6C). All of these findings indicate that c-IAP1 
might mediate the effects of caspse-9b on NF-ΚB signaling and the lung cancer cell survival. 
The above hypothesis was supported by results showing that down-regulation of c-IAP1 
abolished the activating/inhibitory effects of caspase-9b on the NF-ΚB pathway, particularly the 
level of NIK and IκB-α (figure 2.7A and B) and the ubiquitination of RIP1 and NIK (figure 
2.7C). Importantly, c-IAP1 depletion also abrogated the enhanced cell survival conferred by 
caspase-9b expression (figure 2.7D). Taken together, it is likely that c-IAP1 mediates the action 
of caspase-9b on the NF-κB signaling to enhance the survival of NSCLC cells.  
7.5 Caspase-9b directly binds to c-IAP1 
Several proteins of the inhibitor of apoptosis protein (IAP) family members, particularly 
XIAP and c-IAP1/2, have been known to associate with the processed caspase-9 via the IAP-
binding motif (IBM) motif on caspase-9 (16, 59). This four-residue motif has been conserved 
during evolution and it is also present in the IAP-interacting protein Smac/DIABLO of 
human/mice and in a group of pro-apoptotic factors, Reaper, head-involution defective (Hid), 
Grim and sickle (Skl), of Drosophila (hence, also known as Reaper–Hid–Grim, RHG, motif) 
(59). The truncated caspase-9b still retains the IBM and thereby possibly binds to c-IAP1 to 
modulate the NF-κB signaling. This possible direct interaction was validated by 
coimmunoprecipitation of the endogenous c-IAP1 and ectopically expressed caspase-9b (figure 
2.8A). Furthermore, mutation on caspase-9b at IBM (sequence shown in figure 2.8B) reduced 
the association between c-IAP1 and caspase-9b (figure 2.8C) but did not interfere with the 
interaction between caspase-9b and Apaf-1 (figure 2.8D), which suggests that mutant caspase-9b 
is structurally intact and IBM on caspase-9b is crucial for c-IAP1 binding. Interestingly, although 
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caspase-9 has been reported to bind to XIAP or c-IAP1/2 only if being processed (16, 59), our 
results indicate that full-length caspase-9b (37 KDa) still binds to c-IAP1. Additionally, 
mutations of caspase-9b at the cleavage sites had no effects on its interaction with c-IAP1 (figure 
2.9A). It is plausible that whereas caspase-9 needs to be cleaved to expose the IBM for c-IAP1/2 
binding, the truncated caspase-9b has already had the IBM exposed; thus, no more processing is 
necessary. 
The residue(s) on c-IAP1 required for caspse-9b binding has also been revealed. It has been 
reported that residues in BIR2 and BIR3 domain of c-IAP1 are critical for caspase-9 interaction 
(16). Therefore, these residues were mutated to examine if they are also required for caspase-9b 
binding (sequences indicated in figure 2.10A). Interestingly, only one out of four mutations, 
mutation at D320 on BIR3 of c-IAP1, was shown to abolish caspase-9 binding. Importantly, 
D320A mutation did not affect c-IAP1 interaction with RIP1 (figure 2.10B), which ruled out the 
possibility that D320A mutation impaired the whole c-IAP1 structure. These findings point to the 
importance of residue(s) on BIR3 domain of c-IAP1 for interaction with caspase-9b.  
7.6 Caspase-9b regulates the NF-κB pathways and promotes the survival and 
tumorigenicity of NSCLC cells via direct interaction with c-IAP1     
To examine whether the association of caspase-9b to c-IAP1 is essential for caspase-9b-
mediated NF-κB activation/inhibition, mutated caspase-9b at IBM, which was showed to have 
remarkably reduced binding to c-IAP1 (figure 2.8C), was expressed and NIK/IκB-α level was 
evaluated. As shown in figure 2.11A, expression of IBM-mutated caspase-9b did not 
significantly affect NIK and IκB-α level as expression of wild-type caspase-9b. This finding was 
congruent with the observation that mutation of caspase-9b at cleavage site(s), which was not 
shown to affect caspase-9b binding to c-IAP1, was also not shown to affect the capability of 
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caspase-9b to regulate NIK and IκB-α level (figure 2.9B). Mutation of caspase-9b at IBM also 
resulted in loss of enhancing effect of caspase-9b on the survival (figure 2.11B) and AIG of 
NSCLC cells (figure 2.11C). At tumor formation level, NSCLC cells expressing wild-type 
caspase-9b formed tumors in mice with dramatically higher volume and weight compared to 
control cells or cells expressing mutated caspase-9b (figure 2.11D). Most important, only 
expression of wild-type caspase-9b but not of mutated caspase-9b rescued the reduced survival 
and AIG of NSCLC cells as a result of caspase-9b depletion (figure 2.11E, F and G). Overall, via 
binding to c-IAP1, caspase-9b affects both arms of the NF-κB signaling and enhances the 
survival and tumorigenicity of the NSCLC cells. 
7.7 Caspase-9b augments the E3 ligase activity of c-IAP1   
Given that the E3 ligase activity of c-IAP1 impacts ubiquitination of RIP1 and 
ubiquitination-mediated degradation of NIK (4, 5, 64, 71), caspase-9b likely binds to c-IAP1 and 
promotes its E3 ligase activity. Supporting to this plausible mechanism, co-expression of wild-
type caspase-9b and c-IAP1 was showed to induce the ubiquitination of RIP1 and NIK in a 
significantly higher magnitude than expression of either wild-type caspase-9b or c-IAP1 alone 
(figure 2.12A and B). Addition of caspase-9b into the in vitro ubiquitination assay dramatically 
increased the E3 ligase activity of c-IAP1 (figure 2.12C). Furthermore, the enhancing effect of 
caspase-9b on c-IAP1-mediated ubiquitination was diminished when caspase-9b/c-IAP1 binding 
was interfered by mutation of caspase-9b at IBM (figure 2.12A, B and C). These findings shed 
light on how interaction between c-IAP1 and caspase-9b facilitates the roles of caspase-9b in the 
NF-κB pathways: through binding to c-IAP1, caspase-9b enhances its E3 ligase activity to 
induce ubiquitination of RIP1 for the canonical NF-κB activation and ubiquitination of NIK for 
turning off the non-canonical pathway (figure 2.12D). 
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Table 2.4 List of NF-κB-related genes that expression is affected by down-regulation of caspase-
9b (identified by deep RNA sequencing analysis) 
 
Gene name Gene ID 
BAD   
BAX   
BCL2A1   
BCL2L1  
BCL2L2   
BIRC2   
BIRC3  
BMI1    
C3   
CASP8   
CCL2   
CCL3   
CCL5   
CCNB2  
CCND1   
CD44   
CDC25B  
CDKN1A  
CFLAR   
CLU   
CREB3  
CSNK2A1   
CXCL1    
CXCL2   
CXCL3   
CXCL8    
CXCL10   
ELF3   
EMR1   
ERAP1  
ERBB2   
FAS   
FTH1   
FUCA1   
GDF15   
HMOX1   
ICAM1   
IER3   
IFNL1    
IL15RA   
IRF1   
IRF7   
572 
581 
597 
598 
599 
329 
330 
648 
718 
841 
6347 
6348 
6352  
9133 
595 
960 
994 
1026  
8837 
1191 
10488 
1457 
2919 
2920 
2921 
3576 
3627 
1999 
2015 
51752  
2064 
355 
2495 
2517 
9518 
3162 
3383 
8870 
282618 
3601 
3659 
3665 
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JUNB   
LITAF   
MCL1   
MICA    
MYC   
NAMPT  
NFKB2    
NFKBIA  
NFKBIZ   
NOP14   
PLAU   
PLK1   
PTGS2  
RRAS2   
SDC4   
SENP1 
SENP2  
SMAD3   
SOAT1   
SOCS1   
SOCS3   
SOD2   
TCF12   
TFPI2   
TGFB1   
TGM2   
TNFAIP8  
TNFRSF10B    
TNFRSF1A   
TNIP1  
TP53  
TRAF2   
TRIB3  
WTAP   
XIAP   
3726 
9516 
4170 
100507436 
4609 
10135  
4791 
4792 
64332 
8602 
5328 
5347 
5743 
22800 
6385 
29843  
59343 
4088 
6646 
8651 
9021 
6648 
6938 
7980 
7040 
7052 
25816 
8795 
7132 
10318  
7157 
7186 
57761  
9589 
331 
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Table 2.5 List of NF-κB target genes that expression is affected by down-regulation of caspase-
9b (identified by deep RNA sequencing analysis) 
 
Gene name Gene ID 
BAX   
BCL2A1   
BCL2L1  
BMI1    
C3     
CCL2   
CCL3   
CCL5    
CCND1   
CD44    
CDKN1A  
CFLAR    
CREB3  
CXCL1    
CXCL3    
CXCL10   
ELF3     
ERAP1  
ERBB2   
FAS   
FTH1     
HMOX1   
ICAM1   
IER3     
IRF1   
IRF7   
JUNB     
MICA    
MYC   
NAMPT  
NFKB2    
NFKBIA  
NFKBIZ   
NOP14   
PLAU    
PTGS2   
SDC4    
SENP2   
SOD2    
TFPI2     
TGM2   
TNFAIP8  
581 
597 
598 
648 
718 
6347 
6348 
6352  
595 
960 
1026  
8837 
10488 
2919 
921 
3627 
1999 
51752  
2064 
355 
2495 
3162 
3383 
8870 
3659 
3665 
3726 
100507436 
4609 
10135  
4791 
4792 
64332 
8602 
5328 
5743 
6385 
59343 
6648 
7980 
7052 
25816 
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TNFRSF10B    
TNFRSF1A   
TNIP1  
TP53  
TRAF2    
XIAP   
8795 
7132 
10318  
7157 
7186 
331 
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Figure 2.2 Deep sequencing reveals NF-κB as the signaling pathway affected by caspase-9b. 
A549 cells were transfected with random control, mutant caspase-9b control or caspase-9b 
siRNA for 48 hours. (A) Total RNA were isolated and analyzed by deep RNA sequencing. The 
graph represents all NF-κB-related genes, of which expression was significantly different 
between control samples (random or mutant caspase-9b) and caspase-9b-down-regulated 
samples. Red, up-regulated genes; green, down-regulated genes; higher color intensity indicates 
higher difference in expression level; solid line arrows, genes/factors directly affecting/affected 
by NF-κB transcription complexes; dashed line arrows, genes/factors indirectly 
affecting/affected by NF-κB transcription complexes. Cell localization of these NF-κB-related 
factors was also indicated. (B) Total proteins were prepared and subjected to SDS-
PAGE/immunoblotting for caspase-9 or β-actin. The graphs shown in (A) and (B) are 
representative of n=4 from two independent experiments.  
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Figure 2.3 Caspase-9b affects expression of NF-κB target genes, nuclear translocation and 
DNA binding activity of NF-κB proteins. (A and B) Caspase-9b has effects on the nuclear 
transport of p65 and p52. (A) Cytosolic/ nuclear fractions were prepared from A549 cells 
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours 
(A) and from A549 control cells or cells stably expressing caspase-9b (B). Cytosolic/nuclear 
protein extracts were subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin 
A/C or α-tubulin. (C and D) Caspse-9b affects the expression of NF-κB target genes. Total RNA 
was isolated from A549 cells transfected with random control, mutant caspase-9b control or 
caspase-9b siRNA and relative amount of the canonical (A) or noncanonical (B) NF-κB targets 
was determined by quantitative RT-PCR. (E) DNA binding ELISA for NF-κB p65 or p52 were 
performed using nuclear extracts from A549 cells transfected with random control, mutant 
caspase-9b control or caspase-9b siRNA for 48 hours. Specific or nonspecific competitors (SC or 
NSC) were also utilized. Nuclear extracts from Jurkat or Raji cells were used as positive control 
for p65 or p52 activation. (F) Nuclear extract input in (E) was subjected to SDS-
PAGE/immunoblotting for NF-κB p65, NF-κB2 or lamin A/C. Data are shown as means ± SD 
(n=6 on 2 independent occasions). Statistical significance was evaluated by one-way ANOVA 
followed by a Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001). Experiments in (A) 
and (B) were repeated at least twice.   
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Figure 2.4 Caspase-9b promotes the processing, turn-over and ubiquitination of proteins in 
the NF-κB signaling. (A and C) Down-regulation of caspase-9b increases the processing of NF-
κB2 p100 to p52 and the level of IκB-α (A) as well as NIK protein (C). A549 cells transfected 
with random control, mutant caspase-9a control, caspase-9a, mutant caspase-9b or caspase-9b 
siRNA for 48 hours. Total protein extracts were subjected to SDS/PAGE/immunoblotting for 
NF-κB2 p100/p52, IκB-α, caspase-9, NIK or β-actin. (B and D) Caspase-9b expression 
decreases the processing of NF-κB2 p100 to p52 and the level of IκB-α (B) as well as NIK 
protein (D). A549 cells were transfected with parental empty or C9b-expressing plasmids for 24 
hours. Total protein extracts were subjected to SDS/PAGE/immunoblotting for NF-κB2 
p100/p52, phospho-IκB-α, IκB-α, caspase-9, NIK or β-actin. (E) Down-regulation of caspase-9b 
decreases the unbiquitination of RIP1 and NIK proteins. A549 cells were transfected with 
random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours. Endogenous 
RIP1or NIK was immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/ 
immunoblotting for ubiquitin, RIP1 or NIK.  All experiments were repeated at least twice.   
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Figure 2.5 Activation of the canonical NF-κB pathway contributes to caspase-9b-mediated 
enhancement of the survival and anchorage-independent growth of NSCLC cells. (A, B, C 
and D) Colony formation assays were performed with A549 cells transfected with random 
control, mutant caspase-9b control or caspase-9b siRNA for 48 hours (A), with A549 control or 
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caspase-9b-stably-expressing cells (B), with A549 cells transfected with control adenovirus or 
adenovirus expressing IκB-α or super suppressor IκB-α (IκB-αS) for 24 hours followed by 24-
hour transfection with control adenovirus or adenovirus expressing caspase-9b (C), with A549 
control or caspase-9b-stably-expressing cells transfected with control adenovirus or adenovirus 
expressing IκB-α or super suppressor IκB-α (IκB-αS) for 24 hours (D). Western immunoblotting 
of total protein extracts from cells in each case were also performed for caspse-9, IκB-α, IκB-αS 
or β-actin. (E) Colony formation assays in soft-agar were carried out using A549 cells as in (D). 
The graph presents the average number of colonies on each well of the 6-well plates. 
Representative fields of the soft-agar plates were shown in the microscopic images below the 
graphs, (*) scale bar, 2 mm. Data are shown as means ± SD (n=6 on 2 independent occasions). 
Statistical significance was evaluated by one-way ANOVA followed by Tukey’s HSD test 
(#p<0.05, ##p<0.01, *p<0.005, **p<0.001).  
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Figure 2.6 Down-regulation of cIAP1 has similar effects on the NF-κB pathway with down-
regulation of caspase-9b. A549 cells were transfected with control or c-IAP1 siRNA for 48 
hours. (A) Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for 
cIAP1, NIK, NF-κB2 p100/p52, IκB-α or β-actin. (B). Cytosolic/nuclear protein extracts were 
prepared and subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin A/C or α-
tubulin. (C) Endogenous RIP1or NIK was immunoprecipitated (IP) from cell lysates and 
resolved by SDS-PAGE/ immunoblotting for ubiquitin, RIP1 or NIK. All experiments were 
repeated at least twice.   
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Figure 2.7 Down-regulation of cIAP1 abrogates the activating/inhibitory effect of caspase-
9b on the NF-κB signaling. A549 cells were transfected with control or c-IAP1 siRNA for 48 
hours followed by 24-hour transfection with control adenovirus or adenovirus expressing 
caspase-9b. (A) Total protein extracts were prepared and subjected to 
SDS/PAGE/immunoblotting for cIAP1, caspase-9, IκB-α, NIK or β-actin. (B) Graphs were 
created by densitometry calculation of the results in (A). Data in (B) are shown as means ± SD 
(n=3). Statistical significance was evaluated by one-way ANOVA followed by a Tukey’s HSD 
test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001). (C) Endogenous RIP1or NIK was 
immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for 
ubiquitin, RIP1 or NIK. (D) Colony formation assays were carried out from the above cells. Data 
in (D) are shown as means ± SD (n=6 on 2 independent occasions). Statistical significance was 
evaluated by one-way ANOVA followed by Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005, 
**p<0.001). Experiments in (A), (B) and (C) were repeated at least twice.   
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Figure 2.8 Caspase-9b directly binds to c-IAP1 via the IAP-binding motif. (A) Caspase-9b 
associates with cIAP1. A549 cells were transfected with parental empty plasmid or plasmid 
expressing myc-tagged caspase-9b. Endogenous cIAP1 or myc-tagged caspase-9b was 
coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for 
c-IAP1 or myc. Input was immunoblotted for c-IAP1, myc or β-actin. IgG was also used as the 
control. (B) Schematic representation of protein structure for caspase-9a and caspse-9b. 
Compared to caspase-9a, caspase-9b lacks most of the large subunit, including the catalytic site, 
but retains the caspase recruitment domain (CARD), linker region (LR) and small subunit.  The 
LR contains the cleavage sites (closed triangle indicates the auto-cleavage site and opened 
triangle indicates the site for caspase-3-mediated cleavage) and a conserved IAP-binding motif 
(IBM). Sequences of the wild-type (WT) and mutated (Mut) IBM utilized the study were 
indicated in the text box. (C and D) Mutation at IBM disrupts caspase-9b binding to c-IAP1 but 
not to Apaf-1. (C) A549 cells were co-transfected with FLAG-tagged cIAP1 and parental empty 
plasmid or plasmid expressing myc-tagged wild-type (WT) or mutated caspase-9b at the IBM for 
24 hours. FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved 
by SDS-PAGE/ immunoblotting for FLAG or caspase-9. (D) A549 cells were co-transfected 
with FLAG-tagged Apaf-1 and parental empty plasmid or plasmid expressing myc-tagged wild-
type (WT) or mutated caspase-9b at the IBM for 24 hours. FLAG-tagged Apaf-1 was 
coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for 
FLAG or caspase-9. All experiments were repeated at least twice.   
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Figure 2.9 Cleavage of caspase-9b is unimportant for interaction with cIAP1. (A) A549 cells 
were co-transfected with FLAG-tagged cIAP1 and parental empty plasmid or plasmid expressing 
myc-tagged wild-type (WT) or mutated caspase-9b at the cleavage sites (D166A, D181A) for 24 
hours. FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by 
SDS-PAGE/ immunoblotting for FLAG or caspase-9. Myc tagged full-length caspase-9b (37 
KDa, p37) can be cleaved into p10 and myc tagged p27 subunit (if being cleaved at D166 site) or 
into p12 and myc tagged p25 subunit (if being cleaved at D181 site). NS, non-specific band. (B) 
A549 cells were transfected with parental empty plasmid or plasmid expressing myc-tagged 
wild-type (WT) or mutated caspase-9b at the cleavage sites for 24 hours and total protein 
extracts were prepared and subjected to SDS/PAGE/immunoblotting for NIK, caspase-9, IκB-α 
or β-actin. All experiments were repeated at least twice.   
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Figure 2.10 A residue in BIR3 domain of cIAP1 is critical for the association with caspase-
9b. (A) Schematic of c-IAP1 structure. Critical residues for caspase-9 binding have been 
identified mostly in the BIR2 and BIR3 domain of c-IAP1 (white rectangles). c-IAP1 mutations 
utilized in the study were indicated in the text box. (B) A549 cells were co-transfected with myc-
tagged caspase-9b and parental empty plasmid or plasmid expressing FLAG-tagged wild-type 
(WT) or mutated (Mut) cIAP1 in BIR2 domain or BIR3 domain for 24 hours. FLAG-tagged 
cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-PAGE/ 
immunoblotting for cIAP1, RIP1 or caspase-9. Experiments were repeated at least twice.   
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Figure 2.11 Direct binding to cIAP1 is essential for caspase-9b-mediated NF-κB 
activation/inhibition. (A) A549 cells were transfected with parental empty plasmid or plasmid 
expressing myc-tagged wild-type (WT) or mutated caspase-9b at IBM for 24 hours and total 
protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for NIK, caspase-9, 
IκB-α or β-actin. (B) Colony formation assays were performed from stable control cells (A549) 
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or cells stably expressing myc-tagged wild-type (WT) or mutated caspase-9b at IBM. (C) Colony 
formation assays on soft agar were carried out using cells as in (B). The graphs present the 
colony size distribution and the average number of colonies on each well of the 6-well plate. 
Representative fields of the soft-agar plates and representative colonies were shown in the 
microscopic images below the graphs, (*) 2 mm scale bar, (**) 400 μm scale bar. (D) Cell lines 
in (B) or (C) were injected into right flanks of the SCID mice (1.1 × 10
6
 cells/mice). Tumor size 
was measured every week. After 4 weeks, mice were sacrificed and tumor weight was evaluated. 
Data are shown as mean ± SD (n=8). Statistical significance was evaluated by one-way ANOVA 
followed by Tukey’s HSD test (For the left graph, *p<0.005, **p<0.001, WT caspase-9b versus 
control or mutated caspase-9b; for the right graph, #p<0.05, *p<0.005). (E, F and G) A549 cells 
were transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 
hours followed by 24 hour transfection with parental empty plasmid or caspase-9b-siRNA-
resistant plasmid expressing myc-tagged wild-type (WT) or mutated caspase-9b. (E) Total 
protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for caspase-9, IκB-α 
or β-actin. (F)  Colony formation assays were performed. (G) Colony formation assays on soft 
agar were carried out as in (C). Data are shown as means ± SD (n=5 for experiments in panel B 
and n=6 for experiments in panel C, F and G). Statistical significance was evaluated by one-way 
ANOVA followed by Tukey’s HSD test (#p<0.05, ##p<0.01, *p<0.005, **p<0.001).  
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Figure 2.12 Caspase-9b enhances E3 ligase activity of c-IAP1 via direct interaction. (A and 
B) Caspase-9b/cIAP1 binding increases the ubiquitination of RIP1 (A) and NIK (B).  A549 cells 
were transfected with a combination of parental control plasmid/ plasmid expressing FLAG-
tagged cIAP1 and myc-tagged wild-type (WT)/mutated (Mut) caspase-9b at IBM for 24 hours. 
FLAG-tagged cIAP1 was coimmunoprecipitated (coIP) from cell lysates and resolved by SDS-
PAGE/ immunoblotting for ubiquitin, RIP1 or NIK. Input was immunoblotted for c-IAP1, 
caspase-9 or β-actin. (C) Wild-type caspase-9b but not IBM-mutated caspase-9b increases E3 
ligase activity of c-IAP1.  In vitro ubiquitination assay was performed using E1 activating 
enzyme and E2 conjugating enzyme in the presence or absence of FLAG tagged cIAP1 (E3 
ligase) and myc tagged wild-type (WT) or mutated (Mut) caspase-9b. FLAG tagged cIAP1, myc 
tagged WT or Mut caspase-9b was purified by immunoprecipitation (IP) of FLAG/myc fusion 
proteins from cells transfected with plasmid expressing FLAG-cIAP1 or myc-WT/Mut caspase-
9b. In the absence of FLAG-cIAP1 or myc-WT/Mut caspase-9b, FLAG- or myc-
immunoprecipitated products from cells expressing parental empty plasmid were used as 
controls.  (D)  Mechanistic model of how caspase-9b regulates the NF-κB signaling and 
promotes the survival and anchorage-independent growth capacity of NSCLC cells. In this 
model, caspase-9b directly binds to c-IAP1 via the IBM on caspase-9b and residue(s) on BIR3 
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domain of c-IAP1. Caspase-9b/c-IAP1 association enhances the E3 ligase activity of c-IAP1, 
which further elevates ubiquitination of RIP1 and NIK. Ubiquitination of RIP1 stimulates 
phosphorylation and ubiquitination-mediated degradation of IκB-α, allowing the p65-containing 
complexes to translocate into the nucleus and activation of the canonical NF-κB. Via canonical 
NF-κB activation, caspase-9b promotes the survival and anchorage-independent growth capacity 
of NSCLC cells. In contrast, ubiquitination destabilizes NIK, which prevents the processing of 
NF-κB2, nuclear transport of p52-containing complexes and the non-canonical NF-κB activation. 
All experiments were repeated at least twice.   
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Figure 2.13 Down-regulation of cIAP2 has no effect on NF-κB activation and does not 
inhibit the effect of caspase-9b on NF-κB pathway. A549 cells were transfected with control 
or c-IAP2 siRNA for 48 hours. (A) Total protein extracts were prepared and subjected to 
SDS/PAGE/immunoblotting for cIAP2, NIK, NF-κB2 p100/p52, IκB-α or β-actin. (B) 
Cytosolic/nuclear protein extracts were prepared and subjected to SDS-PAGE/immunoblotting 
for NF-κB p65, NF-κB2, lamin A/C or α-tubulin. (C) Endogenous RIP1or NIK was 
immunoprecipitated (IP) from cell lysates and resolved by SDS-PAGE/ immunoblotting for 
ubiquitin, RIP1 or NIK.  
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Figure 2.14 Down-regulation of c-IAP1 increases in c-IAP2 level. (A) A549 cells were 
transfected with control or c-IAP1 siRNA for 48 hours. Total protein extracts were prepared and 
subjected to SDS/PAGE/immunoblotting for cIAP1, c-IAP2 or β-actin. (B) A549 cells were 
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours. 
Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for caspase-9, 
cIAP1, c-IAP2 or β-actin. 
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Figure 2.15 The role of caspase-9b in the NF-κB pathway examined in other cell lines.  
Human bronchial epithelial primary cells (HBEpC) (A) or lung cancer H838 cells (B) were 
transfected with random control, mutant caspase-9b control or caspase-9b siRNA for 48 hours. 
Total protein extracts were prepared and subjected to SDS/PAGE/immunoblotting for NF-κB2 
p100/p52, IκB-α, caspase-9, NIK or β-actin. NF-κB2 p52 were undetectable in HBEpC.  
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Figure 2.16 NF-κB activation in H838, A549 and HBEpC cells. A549 (mutant K-ras, wild-
type p53), H838 (wild-type K-ras, wild-type p53) and HBEpC cells were cultured under the 
same and confluency. (A) Total protein extracts were subjected to SDS-PAGE/immunoblotting 
for NF-κB2, NIK or β-actin. (B) Cytosolic/ nuclear fractions were prepared and cytosolic/nuclear 
protein extracts were subjected to SDS-PAGE/immunoblotting for NF-κB p65, NF-κB2, lamin 
A/C or α-tubulin. 
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CHAPTER 8 – DISCUSSION:  
MECHANISTIC FUNCTIONS OF CASPASE-9B IN THE NF-ΚB PATHWAY 
 
 
 
 
Despite the well-documented function of caspase family in the initiation and execution of 
apoptosis, several studies have implicated caspases in the activation of anti-apoptotic NF-κB 
pathway. Caspases known to activate NF-κB signaling include caspase-1, -2, -8, -10 (9, 37, 38, 
56). The role of caspase-9 in NF-κB activation remains controversial since the CARD domain of 
caspase-9 has been validated to enhance NF-κB activity (61) but in another report, caspase-9 has 
not been shown to activate NF-κB pathway (9). Particular to caspase-9b isoform, there is not 
convincing evidence for its correlation with NF-κB activation and generally, little is known 
about mechanistic roles of caspase-9b outside of its only-known function in inhibition of 
caspase-9a. Importantly, up-to-date studies regarding the mechanistic functions of caspases in 
NF-κB signaling focus mainly on the canonical pathway. Our study emphasized the roles of 
caspase-9b in both arms of the NF-κB signaling, the canonical and noncanonical pathway.   
 Caspase-9b was demonstrated to activate the canonical NF-κB pathway, the only arm of the 
NF-κB signaling reported to promote tumor development in NSCLC (2, 47). Consistent with the 
literature, activation of the canonical NF-κB was shown to mediate the enhancing effects of 
caspase-9b on the survival and anchorage-independent growths of NSCLC cells. To date, the 
majority of studies regarding the contribution of NF-κB signaling to tumorigenesis focus on 
canonical NF-κB pathway and the roles of non-canonical NF-κB pathway in lung cancer 
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development have not been specifically investigated. Caspase-9b regulates both arms of the NF-
κB pathways in the opposite manner, giving rise to an idea that the non-canonical pathway might 
negatively affect tumor-promoting roles of the canonical pathway or activation of the canonical 
pathway. Supporting this hypothesis, non-canonical activation has been observed to prevent 
canonical activation in different ways (1, 39). There is likely a functional interplay between the 
two pathways to fine-tuning the gene transcription activity. Nevertheless, it is unlikely that the 
noncanonical pathway is a compensatory redundant mechanism for the canonical pathway due to 
the observation that when activation of the noncanonical pathway was favored as a result of 
caspase-9b downregulation, there was a significant decrease in the survival and anchorage-
independent growth of NSCLC cells. It is plausible that under the suppressed condition of the 
canonical arm, the non-canonical arm is activated to maintain a basal level of NF-κB activity but 
it is for other biological functions rather than cell survival and growth in an anchorage-
independent manner.  
 NF-κB activation has been implicated in cancer development and resistance to anti-cancer 
drugs (30, 52, 66). NF-κB pathway is thereby an attractive target for cancer therapeutic design. 
Caspase-9b was observed in this study to enhance the survival and anchorage-independent 
growth of NSCLC cells via direct association with c-IAP1 and activation of the canonical NF-κB 
pathway. Hence, targeting NF-κB signaling through interfering caspase-9b-c-IAP1 interaction 
would be a promising approach to inhibit the canonical NF-κB pathway and further compromise 
lung cancer development. An alternative approach to reduce canonical NF-κB activation is 
lowering caspase-9b level in NSCLC cells by down-regulating the expression of caspase-9b or 
modulating the alternative splicing of caspase-9 pre-mRNA to favor the formation of caspase-9a 
instead of caspase-9b. The significance of therapies targeting caspase-9b or caspase-9b-cIAP1 
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interaction is the specificity for cancer/tumor cells as cascape-9b is unnoticeably expressed in 
non-transformed cells (21). In other words, utilization of caspase-9b-targeting approach is ideal 
for cancer-specific treatment. Although NF-κB inhibitors have been shown to be promising for 
therapeutic treatment against cancer, there is a serious concern about using NF-κB inhibitors in 
cancer therapy: suppressing the NF-κB signaling may impair immunity since NF-κB pathways 
play crucial roles in both innate and adaptive immunity. Hence, caspase-9b-targeting approach 
for restricting canonical NF-κB activation would not only be cancer-specific but also address the 
main problem associated with using NF-κB inhibitors in cancer treatment: therapies preventing 
caspase-9b-mediated NF-κB activation would affect the NF-κB signaling only in tumor cells but 
not in normal cells and thereby, have a limited effect on the immunity.  
  c-IAP1 was identified as a key factor mediating the mechanistic and biological roles of 
caspase-9b in the NF-κB pathways. Interesting, depletion of c-IAP2, a closely related IAP to c-
IAP1, was not shown to affect the activating/inhibitory roles of caspase-9b on the NF-κB 
pathways (figure 2.13). Also, c-IAP2 did not compensate for the loss of c-IAP1; specifically, 
elevated level of c-IAP2 as a consequence of c-IAP1 down-regulation (figure 2.14A) did not 
‘rescue’ the blocking effect of cIAP1 down-regulation on caspase-9b-mediated reduction of IκB-
α and NIK level or ubiquitination of RIP1 and NIK (figure 2.7).  Many reports have pointed out 
the critical roles of c-IAPs in the NF-κB signaling; however, it has not been well-documented 
whether exclusive c-IAP1 or c-IAP2 or both c-IAPs play(s) roles in the NF-κB pathways and in 
which circumstances and whether redundant compensatory roles exist between c-IAP1 and c-
IAP2. With respect to the facilitating functions for caspase-9b in the NF-κB pathways, this study 
ruled out the redundant roles between two c-IAPs and highlighted the exclusive roles of c-IAP1 
but not c-IAP2. 
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 The IBM on caspase-9b and and D320 residue in BIR3 domain of c-IAP1 was identified to 
be essential for the interaction between caspase-9b and c-IAP1. Interestingly, despite being 
reported to be important for caspase-9 binding (16), mutation at this residue has not been shown 
to affect c-IAP1 binding to another IBM-containing protein, Smac/DIABLO (54). Three other 
mutations in BIR2 or BIR3 of c-IAP1 have also been utilized in this study and all of these 
mutations have been reported to disrupted c-IAP1 binding to caspase-9 or Smac/DIABLO (16, 
54). However, none of these mutations were observed to decrease c-IAP1 binding to caspase-9b 
(figure 2.10). Another interesting finding regarding c-IAP1/caspase-9b interaction is that 
caspase-9b does not need to be cleaved to binds to c-IAP1 as caspase-9 (figure 2.9). The 
differences in binding mode between c-IAP1/caspase-9b and c-IAP1-/caspase-9 can be explained 
by the possibility that truncated caspase-9b has an altered configuration compared to full-size 
caspase-9, which still interacts with c-IAP1 at BIR3 domain but at different residues and is no 
longer required processing to expose its IBM for binding to c-IAP1.  
 Caspase-9b binds to c-IAP1 and enhances its E3 ligase activity for canonical NF-κB 
activation or noncanonical NF-κB supression. A remaining question is how this interaction with 
caspase-9b augments the E3 ligase activity of c-IAP1. Given that the CARD domain on c-IAP1 
can autoinhibit its E3 activity by preventing the RING dimerization and blocking the access to 
E2 activating enzyme (43), association with caspase-9b might change the conformation of c-
IAP1 from inactive to active form, which would no longer be affected by CARD-mediated 
autoinhibition.  This hypothesis could be addressed by further determination of c-IAP1 structure 
in the binding configuration with caspase-9b. 
 Here we have revealed that caspase-9b exhibits opposing functions in the NF-κB pathways in 
a NSCLC cell line, A549 (wild-type p53 and mutant Kras genotype). The activating roles of 
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caspase-9b in the canonical NF-κB pathway also translated to another NSCLC cell line, H838 
(wild-type p53 and wild-type K-ras genotype) and nontransformed bronchial epithelial primary 
cell line, HBEpC (figure 2.15). However, caspase-9b was not shown to affect the non-canonical 
pathway in either H838 or HBEpC (figure 2.15). This observation could be explained by another 
observation that non-canonical activation is undetectable or relatively low in HBEpC and H838 
compared to A549 cells (figure 2.16). Also, it is likely that the noncanonical pathway might 
negatively impact the canonical activation. In other words, caspase-9b suppresses the 
noncanonical pathway to favor the canonical activation and in cases of cells with noncanonical 
activation at lower level than the basal level for suppressing the canonical pathway, inhibition of 
the noncanonical pathway might be unnecessary.  
 Based on this study, down-regulation of c-IAP1 resulted in similar outcomes as down-
regulation of caspase-9b, particularly the effects on NF-κB pathways (figure 2.6), which supports 
the idea regarding cooperation between c-IAP1 and caspase-9b in regulation of NF-κB signaling. 
Nonetheless, different from caspase-9b, which was demonstrated to promote cell survival, c-
IAP1 reduction did not alter the viability of NSCLC cells (figure 2.7). Since c-IAP1 depletion 
was shown to remarkably increase c-IAP2 level (figure 2.14A), it is likely that c-IAP2 activates 
other survival pathways or inhibits cell death pathways in a NF-κB-independent manner to 
compensate for the loss of c-IAP1. However, this possibility was ruled out by the observation 
that down-regulation of caspase-9b also led to an increase in c-IAP2 level (figure 2.14B). 
Therefore, another possible and more likely explanation for the difference between c-IAP1 and 
caspase-9b with respects to the effects on cell survival is based on the anti-apoptotic function of 
caspase-9b besides its roles in NF-κB signaling. In the absence of c-IAP1 for canonical NF-κB 
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activation to maintain cell survival, caspase-9b might help protect cells from undergoing 
apoptosis by preventing the activation of caspase-9 and down-stream caspase cascade. 
 The canonical NF-kB pathway has been shown to be important for the development of Kras-
induced lung tumor (2). It is plausible that by activating the canonical NF-kB, caspase-9b might 
facilitate Kras-mediated lung tumor formation. Therefore, our future effort will focus on 
determining if caspase-9b cooperates with KRAS mutation to drive tumorigenesis in mouse 
model. Specifically, adenovirus expressing caspase-9b will be delivered to the mutant Kras
G12V
 
transgenic mice to examine whether expression of caspase-9b augments the enhancing effect of 
KRAS mutation on tumoregenesis. If we could validate this hypothesis, targeting caspase-9b 
would be an attractive anti-NSCLC approach for patients carrying KRAS mutation.  
 This study has pointed to the importance of caspase-9b/cIAP1 interaction for tumorigenicity 
of NSCLC cells. Hence, identification of compounds that prevent the binding of caspase-9b to 
cIAP1 would be a potential approach for development of chemotherapeutic drugs to treat 
NSCLC, which is also our future direction besides validating the proposed hypothesis regarding 
the cooperation between caspase-9b and KRAS mutation on tumorigenesis. Specifically, we will 
perform high throughput screening (HTS) for drug compounds that interferes with caspase-9b/c-
IAP1 binding. The first step in this process will be identification and optimization of a high 
throughput assay that allows specific measurement of caspase-9b/cIAP1 interaction.   
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